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Abstract 
In humans, the family of matrix metalloproteinases (MMPs) is composed by 24 closely 
related proteins that share a catalytic zinc ion, responsible for their catalytic activity and a 
typical metzincin fold. Their ability to cleave the extracellular matrix allows them to 
remodel the extracellular space, and change connections from cell to cell through the 
release of ligands present on the cell surface. These changes affect cellular signalization, 
leading to cellular phenotype modification, extending the role of MMPs far beyond that of 
mere enzymes. The alteration of MMPs expression is related to the manifestation of a 
series of severe diseases such as autoimmune pathologies, cancer, myocardial infarction, 
rheumatoid arthritis, Alzheimer's disease. Moreover, MMPs are involved in the control of 
physiological processes such as ovulation, wound healing and growth. For these reasons, it 
is important that their activity at both the transcriptional and post-transcriptional level is 
finely regulated. The regulatory mechanisms are at several different levels: i) induction or 
inhibition of the transcription process, mediated by cytokines, hormones, growth factors, 
and factors which promote tumor growth. ii) regulation and endocytosis of the propeptide.  
iii) activation of the zymogen by the suitable protease. iv) inhibition by physiological 
mediators, such as α2-macroglobulin and TIMPs (tissue inhibitors of MMPs). For this 
reason, in recent years the pharmaceutical research has dedicated many efforts to the 
discovery of zinc-protease inhibitors. In particular, the subject of this thesis has been the 
study of a way of signalization which involves MMPs: the homodimerization process. In 
order to obtain structural information useful for the design of molecules able to control the 
signalization pathways, the involved proteins should be crystallized in complex with 
ligands that induce dimerization. Bi-functional drugs have been generated by linking two 
ligands together chemically and the relative crystallizability
1
 of complexes with mono-
functional and bi-functional ligands have been evaluated. At the very beginning, 
crystallographic studies of some ligands previously synthesized in Prof. Rossello’s 
laboratory (EN238, LC20 and LC29) have been conducted using MMP-12 and MMP-9 as 
model proteins. These compounds were characterized by carboxylate or hydroxamate as 
zinc binding group (ZBG) and by the presence or absence of a linker (Fig.1).  
 
 
                                                 
1
 Antoni, C .; et al. Crystallization of bi-functional ligand protein complexes. J. Struct. Biol. 2013, 182, 246-
254.  
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Figure 1. Chemical structure of compounds used for crystallographic studies. 
 
These analyses have allowed to verify the formation of homodimeric structures when bi-
functional ligands were used (LC20 and LC29) with both MMP-12 and MMP-9. 
Moreover, the formation of a different homodimer was obtained when two molecules of 
the mono-ligand EN238 were crystallized with MMP-12. On the basis of these first results 
during my thesis I carried out: 
 The design and synthesis of a new dual carboxylate inhibitor (SA001, Fig. 2) that 
would enable the formation of a precise homodimer of MMP-12 (previously 
obtained in the presence of two molecules of EN238 with two MMP -12). 
 The synthesis of the hydroxamate analogue of EN238 (LR32, Fig. 2). 
 The synthesis of two additional dual inhibitors with a short ureidic linker, bearing 
a carboxylic acid (CA11) and a hydroxamate (CA14) as ZBG (Fig. 2). 
 
 
 
Figure 2. Chemical structure of the newly synthesized compounds. 
 
All the new inhibitors were tested in vitro on human recombinant MMPs (MMP-1; MMP-
2, MMP-8, MMP-9, MMP-12, MMP-13, MMP-14) by fluorometric assay. Results are 
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reported in Table 1, together with those obtained for the previously described analogues 
(EN238, LC20 and LC29). All compounds showed a nanomolar activity against MMP-9 
and MMP-12 with the carboxylate dual inhibitors (CA11 and LC20) being more selective 
over the other tested MMPs with respect to their hydroxamate analogues.   
 
Table 1. In vitro activity (IC50, nM) on MMPs. 
Compd MMP9 MMP12 MMP1 MMP2 MMP8 MMP13 MMP14 
EN238 508 35 16000 170 115 152 1830 
LR32 2.5 1.5 13 0.16 2.0 0.24 23 
LC20 26 1.3 11800 63 89 35 2200 
LC29 5.5 7.1 280 10 8.9 8.2 250 
CA11 175 4.6 8300 145 134 200 1700 
CA14 26 15 3100 42 15 9 4900 
 
The preliminary crystallographic analysis conducted with CA11 on MMP-9 and on MMP-
12, showed the formation of dimers which, in both cases, appear to be different from those 
formed with LC20. Moreover, CA14 has been crystallized with MMP-8, providing a not 
previously observed dimer.  
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Aims of the thesis 
This work aims to investigate the role of the linker when used to join two different or 
identical chemical entities in a biological context. The chemical structure of the linker has 
been given little importance and the possible interaction that it makes with proteins 
overlooked. The difficulty in going beyond the consideration of length and branch point is 
given by the difficulty in obtaining structural information. In this work we have been able 
to overcome these difficulties and by employing crystallization and X-ray structure 
determination to understand how linker length and branch point influences the inhibition of 
MMPs, our model enzyme system. The results presented here can be used to pursue a more 
detailed structure-guided spacer design. 
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Preface 
In the first chapter the development of selective inhibitors of Matrix Metalloproteinases 
(MMPs) is summarized. The presence of a zinc atom in the catalytic domain of MMPs has 
been exploited to design inhibitors. The first MMP inhibitors relied on recognized peptide 
sequences with the addition of a zinc-binding chemical function. Most MMPs inhibitors 
have been designed with a hydroxamic acid, a strong zinc-binding moiety when negatively 
charged. Non-peptidic, non-hydroxamate based inhibitors with improved inhibitor 
selectivity profile followed. 
Chapter two reviews the use of linkers in biology. They are used to join two functionalities 
to create probes, contrast agents for medical purposes or to add tags for affinity 
purification. In the third chapter the experimental work carried out in preparation for the 
linker study is reported. The methodology to obtain crystals of complexes between an 
inhibitor and a MMPs is detailed and the results obtained reported. The work looks at the 
use of linkers to produce MMP homodimers based on the work with twin hydroxamic 
acids. The fourth chapter describes the chemical synthesis of a bi-functional inhibitor. 
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Chapter I 
THE METALLOPROTEINASIS 
 
1.1 Introduction. 
In the body, the main role of connective tissue is to support other tissues by means of a 
complex organization of cells, fibrils and extracellular matrix (ECM). It participates 
dynamically to maintain the functionality of tissues (blood and lymph) through the 
degradation of connective tissue and is often at the base of diseases of various kinds. The 
remodeling and turnover of connective tissue is regulated by some endoproteases that 
operate by identifying and hydrolyzing peptide bonds. These proteases are classified as: 
 
 aspartate proteases, 
 cysteine proteases, 
 serine proteases, 
 threonine proteases 
 and metalloproteases. 
 
The system of matrix regulation as a functional unit consists of the capillary bed, 
connective tissue cells and autonomic nerve endings. It supports and maintains the 
structure of cells under physical load and during locomotion. The extracellular fluid can be 
reckoned as common area of the three elements listed above. The ECM is also essential for 
morphogenesis and regenerative capacity. This fluid pervades the entire organism, connects 
the lymphatic organs and is the defining feature of connective tissue in animals. The ECM 
includes the interstitial matrix localized in the intercellular space where gels of 
polysaccharides and fibrous proteins create a system able to sustain the cell structure under 
physical load. It is composed by basement membranes that represent a subtle deposition of 
EMC on top of which the epithelial cells rest (Fig.3). 
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Figure 3. Representation of ECM
2
. 
 
This control system regulates the nutrition of the cells (inner circulation) and is responsible 
for the elimination of waste products. It is involved in inflammatory and immune processes 
fundamental for all basic vital processes [1]. Domains of ECM proteins are widely altered 
by different chemical modifications, such as proline hydroxylation to hydroxyproline 
which is necessary for cells, proteolytic removal of the N-terminal and C-terminal domains 
of interstitial collagens, required on membrane cell [2]. 
The principal components of ECM are: collagen, non-collagen proteins and proteoglycans. 
Collagens are a super-family of fibrous proteins that contribute to the structural integrity of 
the cell. They represent 25% of all proteins. Composed by three polypeptide chains with a 
repetitive sequence, the typical structure of collagens is a triple helix. The molecular 
aggregation of collagens with glycoproteins of matrix and proteoglycans leads to a 
supramolecular structure that provides the three-dimensional scaffold from which the 
extracellular matrix is built. 
Among the non-collagen glycoproteins we find laminins, tenascin, thrombospondin, 
vitronectin, elastin. These proteins fold into specific domains that bond together cells, 
matrix glycoproteins, proteoglycans, growth factors, proteases and their inhibitors. The 
increase of one type of non-collagen glycoprotein can influence the activity of other. 
Proteoglycans: These form a complex family; each member is composed of an amino acid 
core and various polysaccharide chains. These multi-functional proteins are capable of 
promoting or inhibiting growth factors, with adhesive and anti-adhesive properties, to 
                                                 
2
 Image available at: 
http://cc.scu.edu.cn/G2S/Template/View.aspx?courseType=1&courseId=17&topMenuId=113299& action 
menuType =1& =view&type=&name=&linkpageID=113468. 
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promote angiogenic processes, control storage, release growth factors and condition 
cellular differentiation. Proteoglycans are divided into two groups: leucine-rich 
proteoglycans and modular proteoglycans. The first type are formed by an alternation of 
hydrophilic and hydrophobic amino acids. Modular proteoglycans are glycosilated proteins 
composed of domains homologous to proteins involved in cell growth, lipid metabolism or 
in adhesion processes such as immunoglobulins and protease inhibitors [18]. 
Tissue remodeling is a complex multi-phase process implicated in pathologic reactions and 
required for physiologic activities. The control of proteolytic activity is extremely 
important for the maintenance of homeostasis. ECM is degraded by several enzymes, 
metalloproteinases, serine-proteases, cysteine-proteases and aspartate-proteinases. High 
turnover and displacement of ECM due to an excessive activity of MMPs leads to an 
intensive degradation of collagen and other ECM components. This unbalancing is the 
cause of inception of several pathology such as tumor invasion and metastasis. [19-20]. 
 
1.2 Metalloproteinases (MMPs). 
MMPs were chosen as model system to to study whether protein homodimerization using 
synthetic twin inhibitors can be used to increase inhibitor selectivity. MMPs were first 
discovered during a study of tissue remodeling during tadpole metamorphosis. The study 
detected the proteolytic activities of MMP-1 (an interstitial collagenase) on collagen, a 
major representative component of the extra cellular matrix (ECM). MMP-1 is able to 
cleave the collagen native triple helix composed of three polypeptide chains. The triple 
helical structure makes collagen  particularly resistant to most other proteases. MMP-1 can 
induce a conformational change in the collagen leading to triple helix opening so that one 
of the three chains positions itself in the active site of MMP-1 [14]. The collagen 
unwinding ability requires the full form of the enzyme because the catalytic domain alone 
is unable to degrade full-length collagen. 
 
MMP-1 is composed by three essential parts: the pro-domain, the catalytic domain and the 
C-terminal hemopexin domain. The pro-domain, located at N-terminus, is needed to ensure 
cellular release. The association between catalytic and hemopexin domains is required for 
collagen degradation. The hemopexin domain is believed to play a role in the local 
unfolding of collagen triple helix [15]. Metalloproteinases are enzymes that contain a metal 
ion cofactor responsible for their catalytic activity. Matrix Metalloproteinases (MMPs) are 
zinc endopeptidases. These proteolytic peptidases are capable of breaking amino acid 
 9 
 
stretches within a protein sequence but may also act as signalization molecules. Their 
ability to cleave the ECM allows them to remodel the extracellular space, and change 
connections from cell to cell and those between cells and the ECM. These changes affect 
cellular signalization, leading to cellular phenotype modification, extending the role of 
MMPs beyond that of mere enzymes. The metal ion is typically coordinated by three 
amino acids. In MMPs three histidines coordinate a zinc ion while in other 
metalloproteinases other metals and other amino acids such as Glu, Asp, or Lys may be 
present. When the pro-peptide is removed, the fourth coordination bond provided by the 
thiol group is assured by a water molecule. 
 
1.2.1 Regulation of MMPs. 
MMPs are secreted and expressed by cells as inactive pro-enzymes: some MMP can be 
directly activated by furine. Since the active site in the pro-peptide form is filled and any 
access to substrates is denied, MMP activation requires cleavage of the pro-peptide. Many 
proteases can cleave the pro-peptide of MMPs, these enzymes belong to the serine 
proteinase family (plasmin) or the MMP proteinase family. The pro-peptide is 80 residues 
long with a highly conserved sequence in most MMPs. In this domain is located a Cys that 
ligates the zinc ion to maintain the latent form of pro-enzyme. In particular, the sulfur atom 
of Cys interacts with the zinc atom present in the active site of MMPs. This interaction 
maintains the connection between the pro-peptide and the catalytic domain and prevents 
MMP activation. A chemical modification of the Cys sulfur atom destabilizes the pro-
enzyme leading to auto-activation by proteolysis. 
The catalytic domain is about 170 amino acids residue long, folds into five-stranded beta-
sheets, three α-helices, and several bridging loops. This domain shows a zinc binding motif 
and one Met residue that forms a “Met-turn” structure. This particular conformation is 
similar to that of other members of matrixins, such as astacins, serralysins. The C-terminal 
hemopexin-like domain is about 210 amino acids, has an ellipsoidal disk shape and is 
necessary for enhanced collagenase activity [5] 
 
MMPs are zinc and calcium dependent enzymes and these ions are required both for the 
stability and for enzymatic activity. They are able to degrade various extracellular matrix 
components in embryo development and growth, processes that requires several bioactive 
molecules and extensive tissue remodeling. Furthermore they play role in the cleavage of 
the cell surface receptors, release of apoptotic factors, activation or inactivation of 
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chemokines and cytokines. MMPs also can affect cell behaviors such as cell proliferation, 
migration, angiogenesis, apoptosis, differentiation, and host defense. MMPs are implicated 
in many physiological and pathological processes mainly associated with inflammatory 
reactions, in blastocyst implantation, ovulation, cervical dilatation, postpartum uterine 
involution, endometrial cycling and hair follicle cycling. MMPs role is complicated to 
define because they have a large spectrum of possible physiologic substrates. 
MMPs act primarily on the cell surface or in the extracellular space and their activity is 
regulated by zymogen activation and their inhibition is operated by endogenous inhibitors 
such as α2-macroglobulin and Tissue Inhibitors of Metalloproteinases (TIMPs). The α2-
macroglobulin has action in the fluid phase, whereas TIMPs are the inhibitors in tissue. 
The α2-macroglobulin is an endogenous glycoprotein of 725 kDa consisting of four 
identical subunits bound together by -SS-bonds [29]. 
TIMPs have high affinity to MMPs and they form a 1 to 1 complex with them. The 
molecular model of TIMP inhibition of MMPs was not understood until the first 
crystallographic structure of a MMP-TIMP complex was solved [16]. This structure 
showed that the contact between inhibitor and enzyme was located on N-terminal sequence 
of TIMP where two Cys are involved in two -S-S -bonds (Cys-X-Cys). The cysteine sulfur 
atom does not interact with the zinc atom of the enzyme active site in contrast to that from 
pro-peptide. The interaction is made by amine of N-terminal domain and with the carbonyl 
group of the first Cys. 
 
TIMPs are composed of a C-terminal domain, an N-terminal domain, 6 loops and 12 Cys 
residues involved in 6 intramolecular -S-S-bonds. The N terminal domain docks in the 
MMP catalytic site where the carbonyl of Cys is able to chelate the catalytic zinc ion 
replacing the water molecule. The C-terminal domain preferentially binds to pro-MMP. It 
is known that TIMPs are able to promote the activation of some metalloproteinases trough 
the formation of tri-molecular complexes: such as pro-MMP-2, TIMP-2, MT-1-MMP. The 
N-terminal domain of TIMP-2 binds the active form of MT-1-MMP inhibiting it while its 
C-terminal domain binds the hemopexin domain of pro-MMP-2. The active form of MT-1-
MMP can process the trimolecular complex by removing the pro-peptide sequence of pro-
MMP-2 which is then fully activated by a second MMP-2. So, low to moderate levels of 
TIMP-2 promote the activation of MMP-2, whereas higher levels inhibit its activation 
because no free MT-MMP is available to remove the MMP-2 prodomain (Fig.4) [31]. 
 
 11 
 
 
 
Figure 4. Cell surface activation of MMP2. A ProMT-MMP is activated during transport to the cell surface 
by an intracellular furin-like serine proteinase, at the cell surface by plasmin or by non-proteolytic 
conformational changes. The activated MT-MMP is then inhibited by TIMP2 and the hemopexin domain of 
ProMMP2 binds to the C-terminal portion of TIMP2 to form a trimolecular complex. An uninhibited MT-
MMP then partially activates the ProMMP2 by removing most of the MMP2 propeptide. The remaining 
portion of the propeptide is removed by a separate MMP2 molecule at the cell surface to yield fully active 
mature MMP2. Mature MMP2 can then be released from the cell surface or bound by another cell surface 
MMP2- docking protein. It can also be inhibited by another TIMP molecule or left in an uninhibited active 
state depending on local MMP: TIMP molar ratios
3
[31]. 
 
TIMPs have additional functions, including promotion of cell growth, matrix binding, 
angiogenesis inhibition and induction of apoptosis. Certain MMPs activities are regulated 
at the transcription level, this includes activation of precursor zymogens, their interaction 
with specific ECM and inhibition by endogenous inhibitors. 
                                                 
3
 Image available at M. D. Sternlicht, Z. Werb, “How matrix metalloproteinases regulate cell behavior”, 
Annu Rev Cell Dev Biol. 2009. 
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Figure 5. Regulation of MMPs. MMP regulatory mechanisms include inductive and suppressive signaling 
(1), intracellular signal transduction (2), transcriptional activation and repression (3), post-transcriptional 
mRNA processing (4), mRNA degradation (5), intracellular activation of furin-susceptible MMPs (6), 
constitutive secretion (7), regulated secretion (8), cell surface expression (9), proteolytic activation (10), 
proteolytic processing and inactivation (11), protein inhibition (12), ECM localization (13), cell surface 
localization (14), and endocytosis and intracellular degradation (15)
4
. 
 
 
 
The first step in MMPs regulation is at the transcription level. Many genes of MMPs are 
inducible by effectors such as growth factors, physical stress, cytokines and oncogenic 
cellular transformation. There are also suppressive agents such as growth factor beta, 
glucocorticoids (Fig.5) [5]. The second regulatory step involves post-translational 
modifications: most of MMPs are released as inactive zymogens and their activation is 
under control of several effector molecules. 
MMPs were identified because of their involvement in homeostasis and turnover of the 
extracellular matrix (ECM), later they were found to act also on cytokines, chemokines and 
protein mediators to regulate various aspects of immunity and inflammation. Degradation 
products of matrix proteins involved in cellular behavior regulation, playing a key role in 
regulating extracellular matrix degradation, and MMPs are involved in numerous processes 
of tissue remodeling associated with cell growth and development and in various 
                                                 
4
 Image available at: M.D.Sternlicht, Z. Werb, “How matrix metalloproteinases regulate cell behavior”, 
Annu Rev Cell Dev Biol. 2009. 
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pathologies. 
 
1.2.2 Classification and structure of MMPs. 
At the moment 24 types of MMPs have been identified in humans. Among the 23 genes in 
the human genome coding for these proteins, we can distinguish 17 MMPs secreted in the 
extracellular matrix and 7 Membrane-Type Metal Protease (MT-MMPs) anchored to the 
cell membrane through a trans-membrane domain and a cytoplasmic C-terminal extremity. 
Numerous are the homologies among the members of this family, so to allow a 
classification, the first discriminating factor is the type of substrate hydrolyzed. These 
proteases are expressed on cell surfaces (such as MT-MMPs) or are secreted by cells. 
MMPs are classified into six sub-groups according to their functionality; Gelatinases, 
Collagenases, Stromelysins, Matrilysins, Membrane-type MMPs and other MMPs. The 
most used MMPs classification is partly based on their cellular localization and on the 
historical assessment of substrate specificity. 
 
1. Collagenases, namely MMP-1, MMP-8, MMP-13, and MMP-18, cleave interstitial 
collagens I, II, and III, and act on ECM and non-ECM molecules. Four types of 
collagenases were identified and only three of them are present in humans and have 
collagen I, II and III as substrate (this constitutes 90% of the total of collagen). 
Each one prefers a particular type of collagen, with Collagenase-1 (MMP-1; also 
called "interstitial collagenase") having greater affinity for the collagen type III,  
Collagenase-2 (MMP-8; also called "neutrophil collagenase") preferring type I 
collagen, while Collagenase-3 (MMP-13) favors collagen type II as a substrate.  
 
2. Gelatinases (MMP-2 gelatinase-A, MMP-9 gelatinase-B) degrade collagen type IV, 
which is the constituent of basal laminae. Their role is to digest denaturated 
collagens and gelatins. These enzymes are different from the previous ones because 
of an additional domain spliced into the catalytic domain. In fact they have three 
repeats of a type II fibronectin domain inserted in their catalytic domain used to 
bind to gelatin, laminin and collagens. MMP-2 digests type I, II and III collagens, 
instead MMP-9 is not able to do so. Gelatinase B (MMP-9) is also capable of 
hydrolyzing the collagen type I, V, VII, X and XII and other proteins such as 
fibronectin, laminin and elastin. The collagen triple helix breaking-up mechanism 
involves binding collagen, followed by a triple helicase activity that liberates a 
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bound collagen that is then hydrolyzed. The ability to destabilize the collagen triple 
helix is a property shared by both collagenases and gelatinases. 
 
3. Stromelysins (MMP-3 stromelysins-1, MMP-10 stromelysins-2). These two 
enzymes are able to cleave the ECM but are unable to cleave the triple-helical 
fibrillar collagens. MMP-3 has a proteolytic efficiency higher than MMP-10; 
stromelysins-1 is able to activate several pro-MMPs. MMP-11 is called 
stromelysin-3, but its sequence and substrate specificity is different from that of 
other stromelysins and is grouped with the “other MMPs”. These do not have a 
helicase activity, but they degrade components of the extracellular matrix such as 
proteoglycans and proteins like laminin and fibronectin. While stromelysins -1 and 
-2 seem functionally related with similar roles and substrate preferences, the 
function of stromelysin-3 remains obscure. It is known that it is expressed in breast 
cancer, and that it is able to inactivate serine protease inhibitors (serpins). This last 
function, also typical of other MMPs, suggests that there may be an interplay 
between the enzyme cascades of serine proteases and metalloproteinases. [33] 
 
4. Matrilysins (MMP-7 matrilysins-1) do not have a hemopexin domain. MMP-7, also 
known as PUMP-1, degrades fibronectin, laminin, some types of collagen that do 
not wind to form a helix and many elements of the ECM. MMP-26, is expressed in 
endometrium cells and operates on a large range of substrates including elastin, 
fibrin and fibrinogen. In contrast to other MMPs, MMP-7 is largely accumulated 
intracellularly. 
 
5. Membrane-Type MMPs. There are four types of transmembrane proteins and the 
last two are glycosyl-phosphatidyl-inositol anchored proteins. They are able to 
activate pro-MMP-2. MT-MMPs and can also hydrolyze ECM components such as 
proteoglycans, gelatin, fibronectin and are involved in the front line in the 
Metallomatrix activation of the same proteases. They are numbered from 1 to 6, 
while the MMP-23 is defined CA-MMP (Cysteine Array MMP) because it has a 
free cysteine in the catalytic site. 
 
6. Other MMPs are MMP-11, MMP-12, MMP19, MMP-20, MMP-22, MMP-23. 
Human macrophage elastase (MMP-12) is involved in the elastin destruction in the 
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lung alveolar wall in the pathogenesis of emphysema and is essential for 
macrophage migration. MMP-19 is known as RASI (Rheumatoid Arthritis Synovial 
Inflammation) because it was discovered in plasma of rheumatoid arthritis patients. 
MMP-20, identified in the enamel of the teeth, digests amelogenin. MMP-21, 
recently discovered in humans, has no known substrates. The function of MMP-22 
is also not known. MMP-23 is mostly expressed in reproductive tissues (Fig.6), [3, 
6, 34]. 
The three-dimensional structure of pro-MMP-2 was determined in 1999 by the group of K. 
Tryggvason showing the typical domain organization of MMPs family members, each 
presenting the autonomous structure and stability. 
 
 
 
Figure 6. Domain structures of secreted and membrane-anchored MMPs. The basic organizations of 
human MMP family members are depicted: S, signal peptide; Pro, pro-peptide; Cat, catalytic domain, 
containing cysteine group (C); Zn, zinc ion; Fn, fibronectin-II- like repeats; Hpx, hemopexin like domain; 
TM, transmembrane domain; GPI, glycol-phosphatidylinositol membrane anchor; C, cytoplasm tail; CA, 
cysteine array; Ig, immunoglobulin-like domain; the flexible linker or hinge region is represented by a wavy 
black ribbon. The domain structure includes the S, which guides the enzyme into the endoplasmic reticulum 
during synthesis, the Pro domain, which sustains the latency of MMPs, the Cat, which houses the Zn
2+
 region 
and is responsible for enzyme activity, the Hpx domain, which determines the substrate specificity, and a 
small hinge region. Additional transmembrane and intracellular domains are also present: the hinge region 
in MMP-9 is heavily O-glycosylated; the furin-activated MMPs and all of the membrane-anchored MMPs 
have a basic motif at the C-terminal end of their prodomains; the MMP-2 and -9 contain three fibronectin-II-
like repeats; four of the six MT-MMPs are anchored to the cell membranes through a type I transmembrane 
domain and the other two through a glycosyl-phosphatidy-linositol moiety. The membrane-anchored MMP-
23, has an N-terminal type II transmembrane domain. The two minimal domain MMPs and MMP-23 lack the 
HPX domain and, in the latter enzyme, this domain is replaced by a C-terminal cystein array (Ca) and an 
immunoglobulin-like (Ig) domain. MMPs are produced in a latent form and most are activated by 
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extracellular proteolytic cleavage of the propeptide and finely regulated by (TIMP)
5. 
 
The members of the MMP family share a primary structure with 40% similarity. Starting 
from the N-amino extremity, the structure of MMPs is composed by: 
 
 signal peptide, 
 N terminal pro-peptide, 
 catalytic site, 
 linker peptide, 
 hemopexin domain. 
 
MMPs are initially in form of zymogens and are accumulated inside the Golgi apparatus 
and then secreted outside the cell. In the cell, the hydrolysis of the signal peptide by 
membrane-type MMP or other proteases leads to the activation of these molecules. This 
hydrolysis is mediated by a “furin-like” convertase. The N-terminal pro-peptide is 
composed of approximately 80 amino acids and is the latency part. Its function is to fill the 
active site to prevent access of substrates. The peptide chain crosses the active site of 
MMPs from C-terminal to N-terminal, an orientation opposite compared to that for the 
substrate. The hydrogen bonding is stronger for pro-domain binding than that for the 
substrate, due to the different orientation. The cysteine has an important role because it 
interacts with the catalytic zinc ion via the thiol group. The pro-peptide sequence is highly 
conserved "Pro-Arg-Gly-Cys-X-Pro-Asp where X represents any amino acid". The 
presence of this part the MMPs characterizes the pro-MMP form [3]. When the pro-peptide 
is removed, the thiol group is replaced by a water molecule, which ensures the zinc fourth 
coordination bond. Similar structure to hemopexin proteins family, has the catalytic 
domain: it has indeed a spheric surface as tertiary structure, allowing protein-protein 
interactions. The catalytic domain contains two or three calcium and two zinc ions. One of 
these zinc ions is directly involved in the catalytic process, while the other and the three 
calcium ions are involved in stabilizing the structure. 
 
 
                                                 
5
 Image available at: F. Manello. What does matrix metalloproteinase-1 expression in patients with breast 
cancer really tell us? BMC Medicine, 2011. 
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Figure 7. Catalytic site of MMPs
6
. 
 
 
The catalytic domain is composed by 170 amino acids folded into one β-sheet composed of 
4 parallel and one antiparallel strands, three α-helices and connecting loops. Within the 
catalytic site various subsites that determine substrate specificity are present. These 
subsites are numbered: S1, S2, S3, Sn, S1’, S2’, S3’, Sn’ and are fitted by portions of the 
substrate denominated P1, P2, P3, Pn, P1’, P2’, P3’, Pn’ (Fig.7). The active site of MMPs 
appears as a series of shallow cavities, except the S1' subsite that is able to accept six 
amino acid residues positioned from S3 to S3'. S1' is considered the most important subsite 
for MMP specificity. It is the deepest in most MMPs except in MMP-1, MMP-7 and MMP-
11 where large side chains such as Arg, Tyr, Glu restrict the size of the cavity. The 
variability in the amino acid sequence of S1' loop, called the specificity loop is responsible 
for the tailoring of the cavity. This characteristic is exploited in the design of specific 
inhibitors for the different MMPs. However, its high flexibility makes developing selective 
inhibitors difficult. The pockets S2 and S3 are similar in various MMP and are shallow, 
whereas S2 prefers hydrophobic groups. 
 
1.2.3 Mechanism of action. 
The catalytic domain is connected to the hemopexin domain by a linker region. This 
hemopexin domain is formed by four blades and its role is in substrate recognition. The 
center of the hemopexin domain contains a pocket which accepts Ca(III?) ions [28]. The 
peptide linker connecting the catalytic domain to the hemopexin domain is rich in proline 
residues. The zinc ion in the catalytic domain is stabilized by three histidine residues. Two 
of them are from an α-helix present in catalytic domain. They are separated by three highly 
conserved residues with a HEXXH motif. These two His residues are situated on the same 
face of the α-helix to achieve an ideal orientation to chelate the catalytic zinc atom. The 
                                                 
6
 Image available at: Nuti, E.; Tuccinardi, T.; Rossello, A. Current Pharmaceutical Design, 2007, 13, 2087-
2100, [40]. 
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third His residue is located on a loop within the active site. These three residues belong to a 
highly conserved sequence in the MMP family, HEXXHaaGaaH. The conserved Gly 
residue is important for the correct folding of the structure. In this way three His are able to 
interact with zinc atom present in the active site. The zinc atom is tetra-coordinated where 
three bonds are made with the three His and the fourth bond is with a Cys residue of the 
pro-domain in the pro-form. Instead, in active form, a water molecule occupies that 
position and participates in hydrolysis. The α-helix of active site propeptide chain 
progresses from right to left in the standard representation of catalytic domain structure of 
MMPs where the zinc atom is to the left of the P1' pocket. After the first His there is one 
Glu: this residue is orientated towards the zinc ion and interacts with a water molecule. The 
role of the Glu is to act as an acceptor/donor of protons in the enzymatic reaction. In the 
hydrolysis mechanism, the interaction of the water oxygen atom with the zinc atom leads 
to a polarization of this molecule promoting a OH
-
 formation. The formation of this specie 
is favored by a proton release from the water molecule to the Glu residue; thus the COO
-
 
group of the Glu side chain is able to pass to the COOH state. At the same time, the natural 
substrate is positioned in the pocket of active site and the carbonyl group of its peptide 
chain is orientated toward the zinc atom. 
Thus the coordination state of the zinc atom shifts from the tetra- to the penta-coordinated 
state. This transitory structure favors the nucleophilic reaction. The carbon of carbonyl 
group is polarized because it makes an interaction with the zinc atom and is attacked by an 
OH
-
 ion. This reaction leads to a change of transition state; the carbon of peptide chain 
passes from sp2 state to sp3 state. 
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Figure 8. Catalytic cycle for the proteolytic mechanism of stromelysin-1 (MMP-3)
7
. 
 
This transition state is stabilized by an interaction between the glutamate residue and the 
zinc atom. After peptide chain opening, on breakage of the C-N bond, the proton on the 
glutamate residue passes to the nitrogen, forming a free amine function (Fig.8) [17]. There 
are some structural and functional differences among MMP family members. Among the 
collagenases the presence of the hemopexin-like domain is important, because it is 
responsible for the specificity, determining which amino acids sequences of interstitial 
collagen are most efficiently degraded. 
It is fundamental in activating pro-enzymes. Matrilysins do not have this domain, while in 
gelatinases it has a similar structure as matrix proteins. MMP-12, MMP-19, MMP-20 and 
MMP-27 are new group of MMPs. The physiological action of these new members of 
MMPs family regards collagen and elastin, fundamental in animal cells. MMPs operate 
through degradation and subsequently on reconstruction of connective tissues: these 
actions are implicated in various diseases such as cell migration, differentiation and 
                                                 
7
 Image available at: V. Pelmenschikov, P.E.M. Siegbahn, “Catalytic Mechanism of Matrix 
Metalloproteinases: Two-Layered ONIOM Study”, Inorg. Chem. 2002, 41, 5659-5666; [32]. 
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growth, but also inflammatory process, neovascularization, wound healing, apoptosis, 
uterine cycle, embryonic development ovulation and in angiogenesis process. Indeed 
MMPs are produced by endothelial cells and several of those have the ability of 
stimulating the new blood vessels building [3]. 
 
1.2.4 Implication of MMPs in pathologies. 
In the complex network of injury tissue response are involved proteinases, through their 
action on matrix remodeling and by their influence on cellular behavior. Plasminogen 
system is an enzymatic cascade involving many members of the serine proteinase family. 
Many experiments on mice with a plasminogen system component deficiency, have been 
reported in literature. In these experiments, it has been demonstrated that the plasminogen 
system is involved in many diseases, promoting tissue destruction or healing by direct or 
indirect activation of matrix metallo-proteinases. Proteinases influence diseases 
progression in different ways: examples are unusual cytokine activation, alteration of 
extracellular matrix turnover, growth factor availability and blood vessel formation. In 
homeostasis conditions all these functions are usually balanced: in fact the activity of all 
proteins is regulated by different factors such as expression and transcription of gene 
levels, levels of pro-enzymes and specific proteinases inhibitors. The dysfunction of 
interactions between the extracellular matrix and organs leads to the development of 
pathologies. [1] After cell stimulation, pathological levels of MMPs and TIMPs are 
detected in  the inflammation area. An example that help us understand the relationship 
between TIMPs and pathologies is given by studies concerning the reduction of TIMP-3 
expression which leads to an adverse matrix remodeling in a cardiomyopathic hamster 
model and in failing of human heart [6]. 
MMP-20 (enamelysin) digests amelogenin that is present within newly formed tooth 
enamel. The pathology called amelogenin imperfect is a genetic disorder, involving a 
mutation of MMP-20 cleavage sites, leads to imperfect enamel formation [6]. Experiments 
with mice deficient in MMP-12 (metalloelastase), did not develop emphysema in response 
to long time exposure to cigarette smoke compared to the wild type reference. Deficient in 
MMP-12, macrophages cannot penetrate the basement membrane neither in vitro nor in 
vivo. The various subtypes of MMPs have been implicated in the dissemination of cancer 
cells by breaking down ECM. This event might create a suitable starting environment able 
to support the initiation and maintenance of growth of primary and metastatic tumors [5]. 
Another example of MMP-12 involvement in pathologies comes from an animal model of 
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experimental autoimmune encephalomyelitis (EAE). These studies have shown in different 
ways which MMPs are implicated in the ability of  leukocytes and T cells to penetrate 
ECM barriers and pass through the basement membrane of  cerebral capillaries (Fig.9). 
 
 
Figure.9 Mechanisms by which MMPs contribute to neurophatology
8
. 
 
Leukocytes express matrix metalloproteinases to facilitate their entry into the central 
nervous system. This process disrupts the basement membrane that surrounds the 
vasculature and results in blood-brain barrier impairment. In the central nervous system, 
high MMP content and its indiscriminate localization result in perpetuation of an 
inflammatory response, which contributes to demyelination and neuronal or 
oligodendrocyte death [7]. 
 
In other studies, mice with MMP-12-null have been used: they had in fact macrophages 
with a lower capacity of penetrating the basement membrane [7, 22]. Presence of ECM is 
essential for cells life, as previously mentioned, in cell growth processes. Several 
pathologies (tumor invasion and metastasis) often show degradation of ECM by different 
types of enzymes like serine, threonine proteases and matrix metalloproteinases. The 
degradation of ECM by MMPs may alter cellular behavior and phenotypes. Unbalanced 
levels of MMPs and their loss of activity control, are distinctive elements common in 
                                                 
8
 Image available at: V. W. Yong, C. Power, P. Forsyth and D. R. Edwards, Metalloproteinases in biology and 
pathology of the nervous system, Macmillan Magazines Ltd, 2001, 502-511; [7]. 
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arthritis, cancer, atherosclerosis and aneurysms. TIMPs are specific natural inhibitors of 
MMPs, they act on MMPs present in tissues with 1:1 stoichiometry. 
The TIMPs are glycoproteins with molecular weight of 21-34 kDa, denominated TIMP-1, -
2, -3, -4. They differ from each other in their solubility, diffusion rate and their interaction 
with  MMPs. TIMP-2 is constitutive and widely expressed in organisms. TIMP -1, -3, -4 
are inducible and are found in different types of cells, among these, TIMP-4 is tissue 
specific, concentrated in brain and ovary cells, in adult cardiac cells and in skeletal muscle. 
TIMP-1 is a weak inhibitor of MT1-MMP, MT3-MMP, MT5-MMP and MMP-19. TIMP-2 
and -4 are inhibitors of gelatinase, whereas TIMP-3 is an excellent inhibitor of ADAMs, 
especially TACE [38]. 
 
In pathological events MMPs levels are often altered. Such altered levels are matched by 
altered levels of TIMPs to control their activity. TIMPs contain an N-terminal and C-
terminal domain with each containing three disulfide bonds. In the N-terminal domain 
there is a separate subunit responsible of inhibition of MMPs. An example that correlates 
TIMPs and pathology regards the reduction of TIMP-3 where it has an adverse effect on 
matrix remodeling in a cardiomyopathic hamster model and in humans is involved in heart 
failure. In an atherosclerosis mouse model an over-expression of TIMP-1 leads to a 
reduction in lesion extension [6]. 
 
1.2.5 Target structure and functions.  
 
 MMP-8 
 
Figure 10. Domain structure of MMP-8. 
 
Matrix metalloproteinase 8 (MMP-8) is also known as collagenase-2 or neutrophil 
collagenase. These alternative names highlight its two main functions. First MMP-8, 
member of the collagenases, can cleave the triple helix structure of native collagen. This 
lytic activity requires cooperation between its catalytic and hemopexin domain [89]. In 
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addition, MMP-8 is rapidly released upon activation of neutrophils, ensuring rapid 
availability in the site of inflammation. Only 15-20% of the cellular content of MMP-8 is 
freely released from polymorphonuclear cells (PMN), while most of MMP-8 is localized 
on the cell surface. The latter is a powerful "membrane-bound": about 90% of the PMN 
cell surface, in fact, processes the collagen type I, and is resistant to inactivation of TIMPs 
and might therefore be most important during inflammation, healing and other 
physiological process [90]. The MMP8 released by neutrophils is heavily glycosylated 
[91]. In addition to the PMN-derived full-length MMP-8 (80 kDa) form, other MMP-8 
species with lower molecular mass (40-60 kDa), were identified. These poorly 
glycosylated forms derived from other cell types [92] and are secreted into the extracellular 
environment immediately after their synthesis. These proteases play a role in the 
development of an inflammatory response but it seems that they have also an anti-
inflammatory action during the healing process [73]. MMP-8 is heavily involved in lung 
diseases: in fact, is the most potent collagenase that degrades type I collagen, the major 
ECM component of the lung [93]. MMP8 is also able to modulate numerous mediators of 
inflammation. Lung disorders are associated with a high degree of oxidative stress: MMP-
8 is highly sensitive to the activation of ROS (reactive oxygen species) [94]. High levels of 
MMP-8 were found in adults [95] and children [67] suffering from acute lung injury in 
their lung secretion. Other involvement of this MMP is in obstructive lung disorders. 
Studies conducted on children showed that macrophages and eosinophiles, in particular, 
release high levels of MMP8 while in healthy persons, neutrophilis are the main source of 
MMP-8. In addition, this metalloprotease is expressed in a variety of cells involved in the 
development of atherosclerotic plaque, in particular in endothelial cells, vascular smooth, 
muscle cells, and macrophages [96-97]. 
 
 MMP-9 
 
Figure 11. Domain structure of MMP-9. 
 24 
 
The MMP-9 is a dependent Zn
2+
 endopeptidase, synthesized and secreted as a zymogen. 
The native form has a N-terminal sequence that allows to direct the protein to the 
endoplasmic reticulum. There is a "pro-domain" which allows to keep the enzyme in a 
latent form: this propetide of 80-90 residues contains a unique Cys of which sulfhydryl 
group coordinates the zinc ion in the active site to keep the enzyme in the inactive form. 
Moreover, there is a "catalytic domain", characterized by a conserved zinc-binding region. 
The activation of pro-MMP-9 is mediated by plasminogen activator/plasmin system. In 
addition, the hemopexin/vitronectin-like domain is connected to the catalytic domain 
through the linker region. This hemopexin domain is responsible for binding to some 
substrates, for membrane activation, is involved in some proteolytic activities and in the 
bond with TIMPs (TIMP-1 and 3). In particular, TIMP-3 is involved in the control of the 
MMP-9 activity [82], whereas its expression is controlled by cytokines, growth factors 
such as EGF (Epidermal Growth Factor), PDGF (Platelet Derived Growth), by interferons 
and interleukins. The main biological function of MMP-9 is the degradation of the proteins 
of ECM such as decorin, elastin, laminin, gelatin, and colagen type IV, V, XI, XVI. 
Physiologically, like other MMPs, MMP-9 is involved in tissue remodeling processes and 
therefore in embryonic development, neuronal growth, angiogenesis and ovulation. A high 
expression of MMP-9 was detected by Sakata et al [83] in the epithelial tumor of the ovary 
and in the lymph node metastases of ovarian carcinoma cells. Other studies show excessive 
levels of MMP-9 expression, in patients with pulmonary lymphangioleiomyomatosis [84]. 
An up regulation of MMPs, in association with a decrease of TIMPs in biological fluids, 
were found in multiple sclerosis (MS) patients and in animal models in which the disease 
was induced. The hypothesis of an involvement of MMPs in the treatment of MS was thus 
considered [85]. Indeed, significant levels of MMP-9 related to the various courses of MS 
were found [86]. A link between high levels of MMP-9 both in the cardiovascular risk [87] 
and with coronary artery disease [88] was also found. 
 
 MMP-12 
 
 
Figura 12. MMP-12 domain structure. S, signal peptide; Pro, propeptide; CAT, catalytic domain; PEX, 
hemopexin domain. The flexible, variable length linker or hinge region is depicted as a wavy black ribbon. 
 
MMP-12 is secreted in its inactive form (54 kDa) and subsequently processed to its active 
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form, following loss of the end N- and C-terminal domain (22 kDa). Both the mRNA and 
protein were detected in alveolar macrophages [81]. MMP-12 is mainly produced by 
macrophage, and involvement of this protein with skin diseases [99], atherosclerosis [100], 
aneurysms [98] and cancers [101], have been demonstrated. In addition, this 
metalloelastase seems to play a predominant role in the pathogenesis of chronic lung injury 
and, particularly, in emphysema. MMP-12 is able to degrade several substrates including 
elastin, which represents 2.5% of the dry weight of the lung and is widely distributed in 
these organs. This metalloprotease is very important for the elastic recoil of the small 
airways and their ability to resist to negative pressure collapse [27]. MMP-12 is the major 
enzyme that leads to the lysis of alveolar elastin magrophages [81]. Preclinical studies on 
COPD (Chronic obstructive pulmonary disease) / emphysema include the blocking of 
MMP-12 as a possible viable therapeutic approach. 
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Chapter II 
LINKERS 
 
2.1 Linkers in biology: different techniques that use linker strategy. 
Linkers are used in many disciplines. In immunology, spacers are used to produce 
monoclonal antibodies against small compounds, referred to as haptens. Haptens are 
intrinsically non-immunogenic because of their small size and must be linked to a carrier 
protein to stimulate an immune response. The B-cells produced in response to the 
immunization, are then selected for their ability to produce antibodies that recognize the 
hapten. Linkers are also part of anticancer drugs such as camptothecin. This powerful 
anticancer is already in therapeutic use. Camptothecin is a natural molecule with cytotoxic 
activity. It is indeed capable in inhibiting topoisomerase I, inducing cell death. Several 
attempts have been made to develop clinical camptothecin analogues with comparable 
anti-tumor cytotoxic activity. Drugs conjugates were designed as powerful camptothecin 
analogues using monoclonal antibodies (mAbs). Antibodies were conjugated with the drug 
via either a dipeptide or a glucuronide-based linker. Aniline containing camptothecin-
analogues have been used to create a site of linker attachment using carbamate bonds, 
which are stable in blood circulation. Dipeptide and glucuronide drug linkers were 
designed with self-immolative spacers for drug release through lysosomal degradation after 
internalization of the complex into antigen-positive cell lines. The camptothecin drug 
linkers were conjugated to three different antibodies [8]. 
In the peptide linker design, appropriate parameters, such as flexibility and length, were 
considered to be important to obtain a specific spacer to join the ligands together. The 
linker had to be flexible enough to permit the binding to the second site and long enough to 
separate the two receptors from each other. [35] 
 
Linker-length influences the interaction between molecules. In the study of biotinylated 
compounds, the avidin affinity for biotin, decreases when a short linker arm is used in the 
structure of biotinylated compound. The decrease in affinity is due to steric hindrance and 
can be attenuated with longer spacers leading to an increase in detection sensitivity for 
avidin or streptavidin. The longer spacers facilitate the formation of the avidin-biotin 
complex [13]. The proteasome is a catalytic protease, able to degrade unfolded 
polypeptides with no particular substrate specificity and without a particular cleavage 
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pattern. For this reason the design of an ideal and specific class of inhibitors is extremely 
difficult. Through the X-ray structure of Saccaromyces cerevisiae proteasome, and the 
observation of the “unique topography of the six active sites in the inner chamber of the 
protease” has permitted the start of a project to construct a series of specific multivalent 
inhibitors. Taking into account the separation between the active sites, different 
homo/hetero-bivalent inhibitors based on a specific group were designed with 
polioxyethylene spacing elements, to create a structure that gives access to the active site. 
For  spacer design, the proteasome-resistance and flexibility were taken into consideration 
to create a derived structure similar to that of unfolded polypeptide chains that able to enter 
the proteolytic chamber. The length of the spacer was chosen based on inter and intra-
molecular interactions, avoiding steric hindrance, to link two monovalent binding head-
groups to obtain homo- or hetero- bivalent inhibitors, with enhanced binding affinity. The 
inhibitory potency of the bivalent inhibitors is greater the monovalent parent, interpreted to 
be due to bivalent binding. With the idea that the spacer should mimic the polypeptide 
chain of unfolded proteins, following modeling experiments, different compounds were 
designed. The researchers suggest that “even better results may be expected with 
homogeneous spacers of defined optimal length for the various interactive site distances. 
Furthermore, this general principle of bivalency is not at all restricted to the use of peptide 
aldehydes as binding head groups, but could, in combination with more potent and 
selective monovalent inhibitors, result in a new generation of highly specific proteasome 
inhibitors”. [36] 
 
 
2.2 Linker design. 
The linker is an important part of the final coupled synthetic molecule composed of 
biological or chemical entities arranged in controlled spatial relationship. Two ligands, 
different or identical, are connected by the spacer to generate a single entity capable of 
interacting with two active sites from selected proteins. The linker length influences the 
spatial arrangement of the subunits, giving greater or less freedom to the resulting 
structure. In addition to spacing out the two domains to avoiding mutual steric interference, 
a longer linker adds flexibility and allows for more conformational diversity. Linkers 
composed of flexible components, often amino acids, allow movement between adjacent 
subunits. Shorter linkers, composed of a small number of atoms, restrict adjustment 
between subunits so as to be more target selective. Although, by restricting the freedom of 
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adaptation, a certain degree of selectivity can be achieved, the risk of steric hindrance 
increases. To avoid this problem, X-ray crystallography data are extremely important when 
designing a library of synthetic chemical molecules with restrictive properties. Based on 
X-ray data, chemical spacer groups of different size and length can be modeled, first  
starting with flexible linkers and systematically arriving at rigid spacers. 
Another aspect of linkers use in biology, is their influence on the stability of single-chain 
proteins as was noted in the study of the single chain Arc-repressor to conclude that spacer 
length affects the equilibrium, folding kinetics and biological activity. The study of 
Robinson and Sauer on wild-type Arc and an Arc dimer composed identical subunits 
connected with an L1 linker of 15-residues to give Arc-L1-Arc. Other tests, which varied 
the spacer length and composition, obtained single chain variants with efficient 
concentrations in the range between μM and M. These data show that the linker affects 
protein stability by altering the free energy of native and denatured states. The linker length 
required to achieve a stable protein conformation, appears to be well defined and the 
adding or deleting of even a few atoms can have, de facto, a destabilizing effect. The 
decrease in linker length often accelerates folding [10]. 
 
The designing of the linker requires many considerations. Based only on modeling data, it 
is extremely difficult to create a rigid linker able to form a specific homodimer. At the very 
beginning, a good working strategy is to synthesize a variety of flexible linkers of variable 
length, capable of producing different subunit orientations. Subsequently, from information 
that define the nature of the interactions and the length of the spacer, the linker can be 
optimized to allow a better interaction between the two sides of the catalytic domains, 
minimizing steric strain and simultaneously favoring the stabilization of interactions that 
promote complex formation. 
 
In this thesis, initial crystallography studies of inhibitor protein complexes, with particular 
attention to metal proteases, have been carried out to show the formation of a molecular 
complex in which two monomeric inhibitors assemble into a dimeric protein-inhibitor 
complex driven by the coupling with this ligand. 
The monomeric ligand complex involves interactions that stabilize a ligand-enzyme 
dimeric conformation where the intermolecular surface includes two protein surfaces and 
the external moieties from two molecules of inhibitor that do not participate in P1' 
interactions (Fig.13). 
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Figure 13. The MMP-12 packing in the P212121 space group observed for the complex with mono-ligand EN 
238 (PDB entry 4H84; ligand code Y38)
9
. 
 
This arrangement has inspired the design of a unique inhibitor that interacts in a classic 
way in the P1' pocket in order to guard the active site interactions and maintain the level of 
affinity and adding a linker that would allow dimer formation with the hydrophilic and 
hydrophobic interactions found in the spontaneously formed dimer. Modeling studies were 
performed to determine the amendments that could be made to the original monomer 
inhibitor to complete the linker structure. Length, flexibility and functional chemical 
groups, were all elements analyzed to arrive at the final structure. The point for linker 
insertion within the inhibitor and functional groups in the linker itself can be considered 
part of the design to increase the selectivity of the inhibitors for the various enzyme 
subtypes. The role of the linker can extend beyond structural innovation or simple “bridge” 
to become an active functional part of the inhibitor, able to increase the selectivity and 
affinity towards the protein studied. Small differences within members of the same proteins 
family may result in different quaternary associations guided by spacers do not act alone 
but recruit protein-protein interactions to modulate the geometry of the dimeric interaction 
[11]. 
 
Several biological studies are trying to find practical ways to induce dimerization. A 
                                                 
9
 C.Antoni, L.Vera, M. P.Catalani, B.Czarny, E.Cassar- Lajeunesse, E.Nuti, A.Rossello, V.Dive, E. A. Stura. 
Crystallization with bi-functional ligands, J. Struct. Biol. 2013, 182, 246-254 [41]. 
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specifically designed linker, may permit the formation of a precise dimer to simultaneously 
inhibit two molecules through the anchorage of two inhibitors present in two different 
pockets. Thus, a single molecule would interact with two biological structures stimulating 
the formation of homo- or hetero-dimers. The adding or deleting of even a single atom in 
the linker structure can have non-negligible consequences. A linker that is too short cannot 
force two proteins together, as steric hindrance becomes an unbridgeable obstacle, and 
only allow alternative monomeric inhibitor binding. On the other hand, a linker that is too 
long is less able to make use of contributory protein-protein interaction useful in the 
stabilization of the complex. An excessive level of freedom conferred by extravagant linker 
span fails to exploit the selectivity that could be provided by chemical groups within the 
linker. Failure to recruit protein-protein interactions from the external protein surface, is 
returning to the classical manner in which selectivity is based only on sequence differences 
among the various subtypes belonging to the same protein family in a limited region 
around the functionally conserved catalytic region. As linker length increases, only the 
closest chemical groups of the spacer are well positioned to influence affinity and stability, 
while the intermediate extensions add only to the randomization of the geometry. 
Crystal formation, which is sensitive to entropic factors, is also promoted by rigid spacers 
and by dimerization but not by heterogeneity that could result from loss in affinity because 
of steric stress due to an inappropriate design. Crystallographic data needed to design a 
rigid linker that is able to control homodimerization must be acquired in successive steps 
with spacers that become progressively more rigid. 
 
2.3 MMPs as a model. 
MMPs have been used as model in this work to study the homo- and hetero-dimerization 
using synthetic twin inhibitors, characterized by different chemical groups and different 
spacer lengths. Protein-protein subunit interactions are to be found in catalysis processes, 
through hetero- and homodimerization. These interactions are of different types and only a 
few of the dimerization processes are involved in modulation of biological activity. The 
knowledge of three-dimensional structure of proteins, in association with the use of 
modeling studies, could help to define the possible interactions between them. In addition, 
the use of synthetic molecules could contribute to the discovery process, allowing 
identification of pathways in which protein homo- or heterodimerization have a functional 
role. An initial approach involves the testing a monomeric ligand to understand the specific 
interactions at the active site, then evolve towards spacer design finishing with a selective 
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bi-functional ligand. Crystallographic data and comparative modeling studies are 
extremely important because they may provide guidance for spacer design. Several types 
of synthetic ligand joined together by spacer could indeed be used to give a completely 
new approach of signal transduction involved in pathological process. 
 
2.4 Linker design and Twin inhibitors 
The objective of this study was directed towards the continuation of the design of new 
linkers, to obtain bifunctional ligands. Synthetic multivalent ligands, consisting of multiple 
receptor binding moieties joined together by linkers, can be effective to probe signal 
transduction and may be useful for pharmaceutical applications. With these considerations, 
it might be possible to design a library of linker, and therefore of the bifunctional ligands, 
which may subsequently be improved thanks to the data from both crystallographic 
analyzes and biological tests. The linker design is based on X-ray rationally oriented 
synthesis (X-ROS), thanks to which the various parts of the ligand are drawn in subsequent 
steps guided, precisely, from crystallographic data and comparative modeling. A rational 
discovery pathway could start with monomeric ligands, involve a spacer design step and 
finally lead to a bifunctional or self-dimerizing ligand. The choice of rather rigid linker 
may facilitate the crystallization, but its exact design requires the knowledge of the 
structural data obtained by crystallography. For this reason semi-rigid linkers were initially 
synthesized. Initial studies were based on a linker such as the N,N'-Bis-(3-
ethylencarbamoyl-propyl)-isophthalamide (BEPI), which connected two units of 
monomeric inhibitor (S)-1-(([1,1'-biphenyl]-4-ylsulfonyl) (isopropoxy) methyl)-3-
hydroxyurea in P1 position, providing the bifunctional ligand MP24. 
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This study of linkers was enabled by the successful crystallization and structure 
determination of the complex between MP24 and MMP-9. In this homodimeric complex 
stood out the lack of significant interactions between protein and linker, and also the 
folding assumed by the spacer did hypothesize that a shorter linker would provide the 
correct distance and geometry of the twin inhibitor, capable to homo-dimer formation on 
MMPs. It is also necessary to consider that shortening the linker, another branch point 
must be used in the design of bifunctional ligand. Both computational and crystallographic 
studies, showed two exposed sites of linkage exploitable in sulfonamidic inhibitors, P1 and 
P2' sites, in order to obtain two kinds of twin inhibitors: type A (like MP24) and type B, 
respectively.  
 
 
On these basis, new twin inhibitors of type B were synthesized, compounds LC20 and 
LC29, which have been tested on MMPs and studied by X-ray crystallography. For type B 
inhibitors, the N,N'-Diethylen-isophthalamide (DEI) linker could be thought as obtained by 
the superimposition on phenyl ring of two molecules of inhibitor possessing on their P2’ a 
N-ethylene-benzamide (NEB), as half linker (EN238). 
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Chapter III 
CRYSTALLOGRAPHY, CRYSTALLOGENESIS AND 
CRYSTALLIZATION. 
 
3.1 Crystallography, crystallogenesis and crystallization. 
The X-ray crystallography is a method used for determining the atomic and molecular 
structures by collecting the intensities of X-rays diffracted from a crystal. Single crystals 
and a monochromatic (single wavelength) beam are used for data collection. The X-rays 
are scattered by the electron cloud of each atom in the crystal. The periodic assembly allow 
for an amplification of the signal proportional to the number of scattering atoms in the 
portion of the crystal irradiated by the X-ray beam. In a synchrotron n X-ray diffraction 
experiment, a single crystal is mounted on a goniometer head and rotated in the 
monochromatic X-ray beam, producing a diffraction pattern of regularly spaced spots 
known as reflections. The diffraction pattern is indexed and the intensity of each reflection 
extracted. Equivalent reflections are merged together to obtain the average recorded 
intensity so providing agreement statistics for the data set. Only the structure factors F (the 
intensity is F
2
) can be calculated from the experimentally obtained intensities, the phases 
of the incident beam needed to calculate the electron density maps  using a Fourier 
transform are lost. They can be obtained by various methods including molecular 
replacement where a related structure is used as a search model to determine the 
orientation and position of the molecules within the unit cell. The phases obtained this way 
are then used to generate electron density maps. Since the search model differs from the 
protein in the crystal the phases need to be improved by fitting the electron density with a 
new model that is progressively refined and completed, thus defining at the end, an 
accurate molecular structure for the components in the asymmetric unit responsible for the 
X-ray scattering. 
The knowledge of the exact molecular structure of a biomolecules helps to guide the 
design and development of potential therapeutic agents. The crystallographic maps provide 
the means to elucidate how potential new drugs interact with their targets and so guide the 
design of specific ligands by revealing the nature of the ligand-enzyme interactions. To 
gain full advantage from a crystallographic analysis well formed, good ordered crystals are 
required. While technical progress in data collection equipment have helped reduce crystal 
size requirements, to achieve this objective a good knowledge about the complex system of 
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crystallization and the various dynamics that influence it are often essential. 
 
3.1.1 Introduction. 
Crystallization is the transition from the liquid state to an orderly solid state, controlled by 
complex kinetic laws. A crystal can be described as a regular arrangement repeated 
indefinitely in three spatial dimensions, called the crystal lattice. Protein crystallogenesis 
extends beyond spontaneous crystallization to involves extra design steps to obtain a well 
diffracting polymorph starting from a protein-inhibitor solution to arrive at a well defined 
crystalline solid state. The crystallization of biological macromolecules is complicated: 
biomolecules require indeed conditions similar to those physiological and their behavior is 
strongly influenced by some variable parameters such as purity, homogeneity (distribution 
of charge, site of glycosilation), pH (protein net charge), temperature (solubility of protein) 
and many other factors. Whatever the crystallization method used, the objective is to drive 
the protein solution into a metastable state of supersaturation, where crystals may form 
(Fig. 14). Crystallization needs conditions in which the transition from a disordered state 
of macromolecules to an ordered crystalline form is possible. 
 
 
Figure 14. Schematic illustration of a protein crystallization phase diagram. Adjustable parameters include 
the optimization of precipitant solution concentration, pH and temperature. The four major crystallization 
methods are represented: (i)micro-bath, (ii) vapor diffusion, (iii)dialysis and (iv) free interface diffusion 
(FID). Each involves a different route to reach the nucleation and the metastable zone, assuming as 
adjustable parameter, the concentration of precipitant solution. The filled black circles represent the starting 
condition. Two alternative starting points are shown for FID because the under-saturated protein solution 
can contain either protein alone or protein mixed with a low concentration of the precipitant agents. The 
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solubility is defined as the concentration of protein in the solution, which is in equilibrium with crystals. The 
super-solubility curve is defined as the separating line conditions under which spontaneous nucleation 
occurs from those under which crystallization solution remains clear if left undisturbed
10
 [13]. 
 
A crystal can be simply defined as a set of protein molecules, assembled into a periodic 
lattice. To induce crystal formation, a fairly high protein concentration is often used 
together with substances that reduce its solubility. The dynamics of the method attempts to 
gradually arrive close to precipitation, so that within the drop, the solubility of the protein 
decreases promoting the formation of some nucleation sites and the subsequent growth of 
crystals. Often, several conditions must be tested before success is achieved. For this 
reason, initial screening involves testing a large array of conditions and then proceeding 
systematically to optimize those conditions that give crystalline particles. 
The crystal formation can be divided into two steps: 
 Nucleation: In various areas of the drop areas with a high concentration of 
macromolecules can be found. Such environment may be appropriate to create an 
ordered microscopic crystalline seed. 
 Crystal growth: The organization of molecules follows that of the initial 
crystalline seed and the crystal dimensions increase. 
 
Good nucleation conditions do not correspond to good crystallization conditions. Each of 
these two crystallization steps are important to get suitable crystals and must to be 
optimized. To reach the so-called supersaturated state, two aspects need to be considered: 
first of all, the rate of incrementation of the effective concentration of the protein and 
secondly the modulation of attractive (electrostatic, hydrophobic/ hydrophilic interactions) 
and repulsive forces [23]. For these reasons precipitant agents, with various properties, 
have been used: the salts have an effect on the ionic strength of the environment, while 
polymers have effect on the solvation layer of the protein and finally the organic solvents 
on the dielectric constant. 
Crystallization is a multi-parameter process where, in order to obtain crystals, it is 
necessary to reach a supersaturation condition, while gradually balancing all the variables. 
The successful study of a crystal includes the definition of its space group and lattice 
packing. 
                                                 
10
Image available at : N.E.Chain, E.Saridakis. Protein crystallization: from purified protein to diffraction-
quality crystal, Nature Methods, 2008, 5, 147-153; [13]. 
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Further aspects must also be taken into account to resolve more difficult problems: 
 
 Protein sequence: Minimization of disordered zones to limit conformational 
heterogeneity during crystallization. Disordered zones are also more likely to be 
proteolyzed. 
 Purity and homogeneity of sample: The concentration of impurities influences the 
crystallization process causing growth termination when impurity segregation is no longer 
possible. 
 Temperature: Controlling the temperature of crystallization, allows for better 
macromolecule stability. It was observed that, at low ionic strength, most proteins are more 
soluble at room temperature than at lower temperature [24, 25]. 
 The nature and concentration of precipitant agents can be exploited to drive the 
proteins into the metastable zone. Precipitants can be grouped in three main sets: 
 Salts (MgCl2, CaCl2, Li2SO4...) affect the ionic strength of the medium; 
 Polymers (PEG) influence the solvation shell around macromolecules; 
 pH controls the net charge of macromolecules. 
 
3.1.2 Sitting drop and hanging drop vapor diffusion. 
During the course of this study, the sitting drop vapor diffusion (VD) method was used, 
practical for setting up rapidly many experiments, while using small amounts of proteins. 
In VD only volatile components equilibrate across the vapor phase that separates the 
reservoir solution from the crystallization drop. The drop consists of small volumes of 
precipitant solution with small volumes of protein solutions mixed together and positioned 
above a larger reservoir containing the precipitant solution. The VD method can be used 
either with a hanging drop or a sitting drop. 
 
 In the hanging drop method, the drop is dispensed on a siliconized cover glass 
which is later reversed when closing the reservoir so that the drop is suspended at the top 
of the crystallization enclosure. The drop is composed of a few microliters of protein-
inhibitor solution mixed with a similar amount of reservoir precipitant solution. A thread of 
vacuum silicon grease is added to the crystallization well to seal the reservoir by pressing 
on the cover glass to isolate the crystallization chamber from the external environment. 
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 In the sitting drop method, the precipitant solution is also situated in the reservoir, 
but a “tower” on which the drop is placed rises from the bottom of the well (Fig.15). 
 
After an initial extensive screening by the sitting drop method with several conditions with 
different compositions of precipitant solutions those specific conditions (varying 
concentrations and type of precipitating agent) that showed a development potential of 
crystals are selected for refinement. The best hypothesis regarding the various parameters 
of crystallization solutions that might have influenced crystal formation, such as the 
precipitant concentration (polyethylene glycol, DMSO and other), pH of the solution, 
presence/absence of salt, are evaluated to design an optimization strategy. The optimization 
process, requires a basic understanding of the physical properties of the solvents. For 
volatile compounds, it is essential to consider the rate of equilibration which is affected by 
the vapor pressure of each of the compounds, while for non-volatile compounds, it is 
necessary to focus our attention on how they may influence vapor equilibration. 
 
 
 
Figure.15 CrysChem sitting drops. 
 
Hygroscopic compounds like glycerol if not in equilibrium on both sides of the vapor 
phase, can lead to an accumulation of water in the partition where its concentration is 
highest. Non-hygroscopic compounds also affect the chemical potential of water [21]. The 
protein-precipitant solution starts at a concentration of protein and precipitant agents where 
it is undersaturated (Fig.14), as water starts evaporating from the drop and moves into the 
reservoir, the protein enters the metastable zone allowing for the crystallization process to 
start. As the concentration of both protein and precipitant in the drop continues to increase, 
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crystals may form and grow (Fig.16). This condition is maintained, until the whole process 
of crystallization is complete. 
 
 
Figure.16 Principe of vapor diffusion: Sitting drop and Hanging drop method
11
. 
 
 
3.1.3 Streak seeding. 
The sitting drop and vapor diffusion methods, allow the equilibration of the precipitating 
agents and the proteins in the drop. Those methods lead to a reduction of the solubility of 
proteins and under favorable conditions crystallization is induced. In order to improve the 
quality of the crystal, it is possible to combine the previously explained methods with the 
streak seeding technique (Fig.17). This technique consist in avoiding spontaneous 
nucleation by introducing microseeds extracted from previously grown crystals. 
 
Figure 17. Crystals grow along the path of the whisker
12
. 
                                                 
11
Image available at: http://centeo.com/en/technical/sitting-and-hanging-drop. 
 
12
 Image available at: http://upload.wikimedia.org/wikipedia/commons/2/2f/Streak-seeding.png. 
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This method uses a cat whisker to collect crystal seeds by touching a previously grown 
crystal in a different drop and then depositing them with the mustache in the new drop. The 
whisker releases seeds along its linear path (streak) across the crystallization drop 
stimulating crystal growth that grow along the length of the track. 
The streak seeding technique has to be done in a particular moment, to introduce seeds into 
the drop within the metastable state. The number of seeds must be limited to allow for 
regular and slow growth. This consideration permits to obtain larger crystals, capable of 
diffracting to higher resolution. 
 
3.2 Crystallization 
“Crystals – familiar to all in gemstones, glittering snowflakes or grains of salt – 
are everywhere in nature. The study of their inner structure and properties gives us 
our deepest insights into the arrangement of atoms in the solid state - insights that 
advance the sciences of chemistry, solid-state physics and, perhaps surprisingly, 
biology and medicine. A century has passed since crystals first yielded their secrets 
to X-rays. In that time, crystallography has become the very core of structural 
science, showing us the structure of DNA, allowing us to understand ... showing us 
how proteins are created in cells, and helping us to design powerful new materials 
and drugs.” [39] 
The crystals obtained from proteins and protein-inhibitor complexes are very sensitive to 
even minimal variations of the environmental conditions. Protein crystals contain typically 
around 50% solvent, mostly in large channels between the stacked macromolecules in the 
crystal. The protein-protein interactions that maintain adherent molecules are generally 
weak hydrogen bonds, salt bridges, and hydrophobic interactions supplemented by 
extensive protein-water and water-water hydrogen bonding. Compared to strong covalent 
or ionic interactions in crystalline minerals, it is easy to understand why protein crystals 
are so fragile. 
 
3.3 Crystals harvesting and data collection. 
Like living creatures and most organic matter, proteins are also susceptible to damage due 
to X-ray exposure. The absorption of ionizing radiation leads to the formation of free 
radicals, which subsequently damages most crystallized proteins. For this reason, a method 
for crystal protection against X-rays has been devised, through the slowing down of the 
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radical kinetics, using  cryogenic cooling. Crystals are harvested using a loop of an 
appropriate size and then transferred into a cryoprotectant solution before being dipped in 
liquid nitrogen. The crystals are stored at ~100 K. The cryoprotectant is required since the 
freezing procedure may otherwise damage the crystals because of ice formation inside the 
crystal lattice. Ice formation can be visualized because of black rings due to the diffraction 
of polycrystalline ice. Such rings can mask the diffraction due to the protein-ligand 
complex and cause partial loss of diffraction data. [21]. The cryoprotective reagents added 
to the solution to minimize the damage by favoring vitrification rather that crystallization 
during cryogenic cooling. The cryoprotection allows for longer data collection times and 
facilitates transport because encased in vitrified solvent the crystal is positionally more 
stable and less likely to be lost. An optimal cryoprotectant will give an X-ray diffraction 
pattern free of powder diffraction rings or "ice rings". A poor choice of cryoprotectant can 
be discerned without X-rays if the drop appears cloudy. Several substances are used as 
cryoprotectants, including polymers (polethylene glycols), organic acids (malonates), 
halide salts in high concentration and volatile or non-volatile (isopropanol) organic 
solvents for biological macromolecular crystals. Such compounds can be used as 
crystallization additives, but for cryoprotection, their concentration is often higher. 
Cryoprotectant optimization is a trial and error procedure so that if the ice crystals form, 
additional agents are added or a different mix of cryoprotectants agents is produced. The 
cryoprotectant compounds enter the crystal lattice during the soaking step depending on 
the duration. Longer soaks are used not only to remove the surface layer, but to permit an 
exchange between the solvent present in the crystal and the one present in the 
cryoprotectant. For long soaks, the time period must be varied to take into account the 
characteristics of the cryoprotectant (concentration, molecular mass and diffusion 
property), the crystal (size, physical stability and hydration state), nature of the 
crystallization solvent and temperature. Typical soak periods range from minutes to hours 
depending on the type of solvent used for the crystallization, the type of crystal, the 
temperature and the type of cryoprotectant [43]. During data collection, the crystal in the 
loop, is aligned along the line of the X-ray beam maintained frozen by a nitrogen gas flow 
at 100 K. Modern data collection advances at synchrotron facilities allow for continuous 
rotation of the frozen crystal around a single axis continuously exposed to X-rays, while 
previously, data collection required discrete angular oscillations around an axis. The X-rays 
that pass through the crystal and are scattered are collected by a detector (Fig.18). The 
collected diffraction spot images, called frames, are displayed on a screen for monitoring 
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the progress and saved for later analysis. The ensemble of these images, recorded from 
different crystal orientations, are processed (integrated, scaled and merged) into a final list 
of indexed reflection intensities. 
 
 
Figure 18. Transition from the crystal to the electron density map
13
. 
 
The number of images depends on the space group and the resistance of the crystal. The 
data collection and processing, done by various computer programs, has been automatized 
extensively so that often a relatively accurate electron density map can be obtained within 
minutes from the moment the data has been finished collecting (Fig.18). The data 
collection process at third generation synchrotron sources can take less than ten minutes. 
 
3.4 Structure definition and refinement. 
Depending on the initial model used in molecular replacement, the electron density map 
can be inaccurate and needs to be improved using a graphic program for model fitting and 
cycles of structure refinement (REFMAC5). Geometry restraints needed by the refinement 
programs for synthetic ligand can constructed using the monomer library sketcher from 
CCP4 program. The generated model coordinates for the molecule allows the ligand to be 
fitted into the difference electron density (Fo-Fc; green: positive, red: negative) map using 
COOT. The model was also refined in phenix.refine to obtain at the end, an accurate 
electron density map of the ligand-protein complex. The the last stages of protein structure 
refinement involve the interpretation of the electron density for the solvent around the 
protein which contributes to the diffraction: water molecules and other molecules from the 
crystallization precipitant or from the cryosolution, typically, glycerol, PEG and other. The 
positioning of these molecules in the electron density map also follows strict geometrical 
criteria. 
The figure above shows the result in terms of definition, of different  resolution values, 
                                                 
13
Image available at: http://www.ruppweb.org/xray/101index.html. 
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expressed in Ångstrom. The example shows the same region of the molecule at different 
resolution settings: 3 Å, 2 Å and 1.2 Å. The ring of phenylalanine is correctly positioned in 
the resolution with 1.2 Å. This can still be done with confidence in the 2 Å cases, but at 3 
Å we observe a deviation of the centroid of the ring from the correct model (Fig.19).  
 
 
 
Figure 19. Data quality determines structural detail and accuracy. The qualitative relation between the 
extent of X-ray diffraction, the resulting amount of available diffraction data and the quality and detail of the 
electron density reconstruction and protein structure model, are evident from this figure
14
. 
 
The more and better data, the more accurate and detailed the final structure model will be. 
An image obtained at a better resolution also contains much more HD data, corresponding 
to the closest sampling distance in the crystal. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
14
Image available at: http://www.ruppweb.org/xray/resolution.html. 
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Chapter IV 
SYNTHETIC INHIBITORS OF MMPs 
 
4.1 MMPs inhibitors. 
Initially, the Tissue Inhibitors of Metalloproteinases (TIMPs) were taken into account as 
potential inhibitors that could be used to control MMPs activity but, given their complexity 
and large molecular size, were not found as suitable inhibitors. For this reason, in recent 
years, many studies have turned to the careful design and synthesis of synthetic inhibitors, 
with defined characteristics, some of which are analyzed in the following paragraphs. 
 
4.2 First approaches of project and synthesis of possible MMPs inhibitors (MMPi).  
At the very beginning, the first generation of synthetic inhibitors were peptidomimetic 
substrate-based molecules [44] which were designed on the basis of a knowledge of the 
amino acid sequence of human triple helical collagen at the site of cleavage by MMP-1. 
However, the disappointing results discouraged the continuation of this approach. 
Progressively, with the use of the X-ray crystallography and multidimensional NMR 
techniques, the early crystal structures of the complexes, between inhibitor and protein, 
were resolved. On this basis, a new class of inhibitors, designed with computational 
techniques, was developed: the structure-based inhibitors [47]. Comparing these two 
classes of inhibitors, it was discovered that the first chemical inhibitors, synthesized in the 
90's, still had the same potential as those peptide one, showing no improvement in potency 
and selectivity towards the metal proteases. Initially, one of the problems that medicinal 
chemists had to face, was the choice of the inhibition strategy. Indeed, it was possible to 
direct the synthesis towards broad-spectrum inhibitors or to choose the synthesis of 
selective inhibitors, turning the interest directly to a specific member of the MMP family 
[52]. The clinical trial data showed disappointing results for the broad-spectrum inhibitors, 
where a common problem was represented by the general poor activity. As a consequence 
of this, the interest was turned to the synthesis of selective inhibitors. 
The design of selective inhibitors was developed in accordance to the "structure-based" or 
"ligand-based" method.  
 The structure-based method: the study is based on the careful analysis of the 
structure of the various MMPs. The intent is to create selective inhibitors, with high 
affinity, through the use of computational and combinatorial techniques [47]. 
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 The ligand-based approach aims to increase the selectivity of the inhibitor by 
varying the P1’ portion of the molecule, in particular the one that fits into the S1’ 
pocket of the MMPs. In fact, this pocket is characterized by high variability among 
the various metalloproteases. 
An effective synthetic MMP inhibitor should have: 
 A functional group capable of binding the zinc(II) ion, present in the catalytic site 
of the enzyme (zinc binding group or ZBG). 
 One or more groups able to make hydrogen bonds with the enzyme backbone. 
 One or more groups able to establish van der Waals interactions with the enzyme 
subsites. 
The first synthetic inhibitors presented a particular sequence (Gly-Ile) in correspondence of 
which the human collagen is hydrolyzed by the action of MMP-1. Later on, their structure 
was improved on the basis of a more specific knowledge of the interaction enzyme-
substrate. It should be stated that the standard nomenclature used for the proteases 
includes:  
 S1, S2, S3, S1', S2', S3', to indicate the enzyme subsites. 
 P1, P2, P3, P1', P2', P3', to indicate the groups present in the substrate (or in the 
putative inhibitor) which interact with the corresponding sites of the enzyme, 
starting from the site of hydrolysis. 
These considerations led to design of three classes of compounds: 
1. Ligands with amino groups only on the left side of the ZBG 
2. Ligands with amino groups only on the right side of the ZBG 
3. Ligands with amino groups present on both sides. 
In particular, those ligands that carried the amino acid sequence on the right side of the 
hydrolysis site (P1' and P2') with a hydroxamic acid as ZBG, recorded a greater activity. 
Moreover, another important factor to consider is how the chemical nature of the various 
ZBG leads to variations of the inhibitory activity: this decreases starting from the 
hydroxamate group, up to the minimum value for the carboxylate group (passing by the 
phosphinate group and amino-carboxylate). The hydroxamate group acts as a bidentate 
chelator, in which each oxygen is located at an optimal distance compared to the catalytic 
zinc (1.9-2.3 A): the bond is further enhanced by interactions with specific residues of the 
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catalytic site, in particular Glu and Ala, which confer rigidity to the geometry. From the 
study of the various structures obtained by X-rays, it is possible to assume that the nitrogen 
of the hydroxamate group is protonated: it would thus be capable of forming a hydrogen 
bond with a carbonyl oxygen of the enzyme. It is clear from the studies [48], that the 
hydroxamic acid group gives more power to the synthetic ligand. Despite these positive 
aspects, however, it should be considered that this group has some drawbacks such as: 
 a rapid biliary excretion; 
 possible hydrolysis to carboxylic acid in vivo, and then decreased binding affinity; 
 toxicity due to degradation to hydroxylamine in vivo. 
The use of groups such as thiol or phosphonate, would lead to the same pharmacokinetic 
problems whereas, the use of other groups, such as carboxylate, would lead to ligands with 
reduced side effects but also with lower binding affinity [48]. 
Experimental studies have led to the design of inhibitors, grouped according to their 
chemical characteristics, in: 
1. peptidic succinyl hydroxamates; 
2. non-peptidic succinyl hydroxamates; 
3. sulfonamide hydroxamates; 
4. non-hydroxamates. 
 
 Peptidic succinyl hydroxamates. 
In this class, it is possible to make some general remarks about the groups P1’, P2' and P3'. 
 Group P1': This interacts with the S1 pocket, which changes among the MMPs: by 
varying the group in this position, it is possible to switch from selective inhibitors 
for gelatinases (with wide P1’ group) to broad-spectrum inhibitors (with small P1’ 
group). 
 Group P2'. After the resulting data from the various X-rays analyses, obtained from 
the complex MMP_inhibitor, it was possible to observe the real orientation of the 
P2' group. This is oriented outside from the enzyme, establishing few contacts with 
the S2' subsite.  
 Group P3'. The introduction of various chemical groups in this position, leads only 
to a modest inhibitory effect on the activity. 
Two inhibitors, characterized by a broad-spectrum of action, were part of this category: 
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Batimastat (BB-94, British Biotech) and Marimastat (BB-2516) (Fig.20a-b). 
 
Fig 20. a) Batimastat, b) Marimastat. 
 
Batimastat (Fig.20a) has a hydroxamate group as ZBG, whose potential antimetastatic and 
antiangiogenic activity was studied by carrying out experiments on rats. The effects 
observed as a result of its use, were: reduction of spontaneous metastasis and inhibition of 
the appearance of lymphatic metastasis in mice with breast cancer. A limitation of this 
inhibitor was its solubility: indeed, it is poorly soluble and has poor oral absorption. 
However, due to strong side effects, its administration was soon interrupted [49]. 
Also Marimastat (Fig.20b) has a hydroxamate as ZBG but presents a hydroxyl as 
substituent positioned in α of the hydroxamic acid, which further increases its water 
solubility and, in particular, allows this compound to be absorbed orally. 
 Introducing some changes in the P1' group of these inhibitors, as in compound c, 
the selectivity increases. Analyzing the case of the insertion of a 3-phenylpropyl 
group, this has allowed to increase the selectivity towards MMP-2, both in the 
succinyl hydroxamates, and in carboxylates and phosphonates. 
 
 
 The P2' group has a strong effect on the pharmacokinetic properties of the ligand: 
the tert-butyl in this position, characterizes active compounds orally, just as 
Matimastat. The accredited hypothesis is that an unwieldy group in this position 
provides the right degree of steric hindrance, thus shielding the adjacent amide 
bond, by limiting the hydration and favoring the passage of the inhibitor across cell 
membranes, during the absorption. 
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 Non-peptidic succinyl hydroxamates. 
Included in this category, there are compounds that result from rupture of the group P2'-P3' 
in the pseudo-peptide structure: an example is Ro 32-3555, selective for collagenases. 
 
 
 Sulfonamide hydroxamates  
Prinomastat (AG 3340), a potent orally active inhibitor, belongs to this class. If compared 
with other structural analogues, it shows a superior efficacy in the lowering of propagation 
and development of tumor metastasis in animal models. It is one example of a second-
generation inhibitor with selectivity over MMP-1 and -7 [45].  
 
 
 
On the basis of these findings, a series of α-amino-β-solfone hydroxyamates have been 
designed, such as compounds d. These have proved to be potent inhibitors of both MMP-2 
and MMP-13. These ligands were allowed to assign: 
 more power to the aryl-ether derivatives rather than thioethers 
 the disubstitution on the alkyl amine placed in α to the hydroxamate, leads to a loss 
of power whereas, the inclusion of simple alkyl amines, provides activities both on 
MMP-2 and MMP-13. 
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 Non-hydroxamates 
The study of these compounds is aimed at the research of different ZBGs than the 
hydroxamate group, in order to eliminate or reduce the characteristic toxic effects. The 
toxicity problems are attributable to the high binding affinity for zinc (II), but also for other 
transition metals, such as Fe (III), Cu (II), Ni (II). These metals are located within the 
structure of metalloproteins, variously distributed in the body: therefore the bond to the 
zinc of MMPs cannot be exclusive. This is the basis of the scarce therapeutic safety of the 
inhibitors of MMPs with hydroxamate group of first and second generation. A first class 
object of study is the one represented by di-thiols, as a replacement to the hydroxamic acid 
group, such as compound e [50a]. 
 
 
 
 
It is an inhibitor both of MMP-2 and MMP-9, with Ki in the order of nanomolar. The 
number of carbon atoms of the side chain do not strongly influence the inhibitor-enzyme 
binding [50].  
 
 4.3 New selective MMPs inhibitors. 
Despite the various problems associated with hydroxamic acid, and the low-potency 
related to the carboxylic acid, additional inhibitors have been designed with these two 
ZBGs, improving the selectivity for the various components of MMPs. Wyeth in 2005 
published a series of biphenyl sulfonamide carboxylate MMPi, with a marked selectivity 
towards MMP-13. Among these, compound f showed a high selectivity over MMP-1 
(IC50=400 μM), MMP-7 (IC50=1.1 μM), MMP-9 (IC50=7 μM), and MMP-14 (IC50=5 μM), 
having a carboxylic acid as ZBG [54]. 
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Subsequently, other inhibitors [57] were generated by using a fused ring system, trying to 
obtain a greater selectivity towards MMP-12: an example is compound g. It was found that 
restricting the rotation of the biphenyl group is favored the binding in the less flexible 
MMP-12 S1' pocket. 
 
 
 
 
Inhibitor g showed a 60-fold selectivity for MMP-12 over MMP-13. This inhibitor 
demonstrated in vivo efficacy in a MMP-12-induced mouse model of pulmonary 
inflammation. In recent years, several research groups have designed molecules with the 
aim of increasing selectivity. Rossello et al. have developed selective hydroxamic acid 
inhibitors of MMP-2 as potent anti-angiogenic agents [55]. The inclusion of alkyl 
substituents, at the carbon adjacent to the hydroxamic acid, has increased lipophilicity and 
therefore, the interactions with the S1 region of the active site, increasing the selectivity of 
the compound towards the MMP-2 (compound h). 
 
 
In the study of Casalini et al, the new fluorinated compound i, arylsulfone-based MMP 
inhibitor, containing carboxylate as ZBG was synthesized as radiotracers for positron 
emission tomography. It showed an IC50 of 16 nM on MMP-2 and an IC50 of 107 nM on 
MMP-9. 
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These are very good potency data considering the carboxylate nature of the ZBG. It has a 
good activity for deep S1′ pocket of MMP-2/9/12/13. This compound showed good 
characteristics of activity and selectivity to be used as a probe in the glioblastoma tumor 
model. In addition, the concomitant inhibition of MMP-12 and MMP-13 should be 
beneficial, because also these enzymes have been recently found to be highly expressed in 
U-87 MG glioblastoma [51]. Now, many research studies are turning their attention to 
structures having non-hydroxamic groups as ZBG, trying to gradually increase the affinity 
and selectivity of these ligands to the protein and, at the same time removing its typical 
side effects. 
 
4.4 Recent advances in matrix metalloproteinase inhibitor (MMPi) design and 
development. 
This paragraph shows three recent synthetic approaches, aiming to develop better 
inhibitors of MMPs, analyzed by Jacobsen et al. [53].  
1. Research of new zinc-binding groups (ZBG); 
2. Study of non-zinc-binding MMPi; 
3. Design of MMPi that form covalent adducts with proteins. 
 
4.4.1 Research of new zinc-binding groups (ZBG). 
The approach adopted with this class of inhibitors is based on the physiological mechanism 
by which MMPs anchor their endogenous substrate, directly involving the catalytic zinc.  
The mechanism initially involves the attachment of the substrate in the catalytic site of the 
enzyme, which is followed by the zinc-bound water molecule attacks the substrate 
carbonyl carbon: after the transfer of protons through a conserved Glu residue to the amide 
nitrogen of the scissile bond, results in peptide cleavage. The purpose of the ZBG in the 
inhibitor molecule is twofold. This group displaces the zinc-bound water molecule and thus 
inactivates the enzyme and, moreover, it ensures the anchoring of the ligand to the 
substrate-binding pockets. As explained in the previous paragraph, all MMPi had one or 
more group ZBG, such as: hydroxamic acid, carboxylic acid, phosphonic acids and thiols 
and among them, the hydroxamic acid stood out as the best chelating group of the zinc 
atom. In particular, the OH group and the NH group of this ZBG, form hydrogen bonds 
with two aminoacids present in the catalytic site: Glu and Ala, respectively. The need to 
find other ZBG, derives from its poor bioavailability in vivo and from the side effects 
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common in many hydroxamate MMPi, such as the muskoloskeletal syndrome (MSS), 
highlighted in clinical trials. Examples of innovative ZBGs are: ZBG I, II, III, IV. 
 
Squaric acid-based hydroxamic acid analogues (ZBG I-II) [58], have been developed to 
target the MMP-1. These new chelators, form a 6-membered ring upon metal chelation as 
opposed to the 5-membered ring of hydroxamic acid.  
 
The compound l was reported to have an IC50 =15μM on MMP-1, with a 18-fold 
improvement compared to its carbonyl derivative.  
 
The particular bond of squaric acid may provide a viable alternative for the precise 
positioning of the inhibitor in the various pockets of MMPs. Further developments are still 
necessary for this new scaffold.  
Another example is ZBG III [59]: its principal characteristic is the preference binding for 
late transition metals. It is a bidentate chelator of the zinc ion, through the nitrogen of the 
pyridine and the oxygen of the carboxylate. This ZBG is 100-fold more potent on MMP-3 
compared to acetohydroxamic acid, but also in this case further studies are needed. 
Another group is represented by heterocyclic bidentate ZBGs, such as ZBG IV [60]. They 
were selected because have common points with the hydroxamic acid, such as: a 5-member 
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chelate monoanionic, with potentially better biostability and tighter Zn
2+
 binding due to 
ligand rigidity.  The search for new  ZBG has led to encouraging results, even if there are 
still concerns about the use of strong metal chelating groups that may preclude the 
development of highly selective inhibitors, due to the highly conserved nature of Zn
2+
 in 
the active site of all MMPs. Many challenges remain for these MMPi, including 
demonstrations of significant improvements of action on MMPs. Also, more and more 
studies on the bioavailability and pharmacokinetics of these MMPi are needed to determine 
if the improvements in these properties are actually conferred by these compounds. 
 
4.4.2  Non-zinc-binding MMPi. 
These inhibitors are based on the fact that by eliminating or minimizing the interactions 
with the catalytic zinc, compounds with increased selectivity towards the MMPs could be 
obtained, because the metal site is well conserved among these proteases. Several of these 
inhibitors (such as compounds m,n) show high MMP-13 selectivity and bind deep within 
the S1' pocket, to induce a specific protein conformation.  
 
 
Some characteristics are common among members of this class: generally, they are long 
molecules with linked aromatic or otherwise planar ring structures, have a carbonyl group 
and N–H groups to offer opportunities for hydrogen bonding interactions with the S1' 
pocket. A major reason for the selectivity of m, is the ability to induce a unique 
conformation in the S1' specificity loop of MMP-13 that is not accessible in other MMPs. 
It is still not completely clear whether this selectivity of action is due solely to the absence 
of ZBG. 
 
4.4.3 Mechanism-based MMPi. 
The activity of these inhibitors is based on the delay of the protein_inhibitor complex 
dissociation. The characteristic mode of action requires that the inhibitor acts as a suicide 
substrate, in which a functional group present on the structure is activated by the zinc 
atom, leading to a covalent modification in the enzyme structure.  
 
 53 
 
 
 
The proposed mechanism for the compound o is that the thiirane group, activated by 
coordination with the zinc atom, leads to the opening of the ring as a result of the 
nucleophile attack on Glu
404
, giving a covalent bond between the carbon of the thiirane 
ring and the amminoacid. This bond ensures the inhibitor to the active site leading to low 
inhibitor dissociation. The use of mechanism-based, slow-binding inhibitors may provide a 
new approach to gain selectivity in MMPi design. 
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Chapter V 
 
INTRODUCTION TO THE EXPERIMENTAL PART 
 
In humans, the family of matrix metalloproteinases (MMPs) is composed by 24 closely 
related proteins that share a catalytic zinc ion, responsible for their catalytic activity and a 
typical metzincin fold. Their ability to cleave the extracellular matrix (ECM) allows them 
to remodel the extracellular space, and change connections from cell to cell through the 
release of ligands present on the cell surface. These changes affect cellular signalization, 
leading to cellular phenotype modification, extending the role of MMPs far beyond that of 
mere enzymes. The alteration of MMPs expression is related to the manifestation of a 
series of severe diseases such as autoimmune pathologies, cancer, myocardial infarction, 
rheumatoid arthritis and Alzheimer's disease. Moreover, MMPs are involved in the control 
of physiological processes such as ovulation, wound healing and growth. For these 
reasons, it is important that their activity at both the transcriptional and post-transcriptional 
level is finely regulated. The regulatory mechanisms are at several different levels: i) 
induction or inhibition of the transcription process, mediated by cytokines, hormones, 
growth factors, and factors which promote tumor growth; ii) secretion and endocytosis of 
the propeptide; iii) activation of the zymogen by the suitable protease; iv) inhibition by 
physiological mediators, such as α2-macroglobulin and TIMPs (tissue inhibitors of 
MMPs). 
 
In recent years, pharmaceutical research has dedicated many efforts to the discovery MMP 
inhibitors as potential agents for anticancer therapy. In particular, synthetic inhibitors of 
MMPs have been proposed and tested as potential anti-invasive and anti-angiogenic 
compounds, characterized by a minor impact on the organism having also minor side 
effects compared to other drugs commonly used in therapy. Early peptido-mimetic 
inhibitors such as batimastat and marimastat, were subjected to clinical trials which 
resulted disappointing due to severe side effects. More recently, other non peptido-mimetic 
compounds were tested in clinical trials. Prinomastat is a compound which presents an 
important turning point in the basic structure of the inhibitors of MMPs: a scaffold carrying 
a sulfonamide group, capable of forming numerous interactions with various amino acids, 
present in the sites closest to the enzyme recognition sites. Despite this, the main 
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limitations of these synthetic ligands are: 
 poor selectivity of action, for their inability to distinguish between the 
various members of the MMP family. 
 heavy side effects, such as arthralgia and loss of consciousness, that occur 
after prolonged therapy and often require the interruption of the latter. 
 
Current knowledge of the three-dimensional structures of these proteins, obtained thanks to 
the use of X-ray crystallography and the determination of the in vitro activity of many 
synthetic inhibitors tested on MMPs, have allowed the acquisition of further information, 
necessary for the synthesis of more specific and more active ligands. Indeed, on the basis 
of recent discoveries, it is known that the pharmacophore should have a zinc-binding group 
(ZBG) capable of complexing the zinc ion, present in the catalytic site and a non peptidic 
portion, oriented towards the sites S1, S1', S2' of the enzyme, capable of establishing 
interactions with those pockets. Important point of selectivity is represented by the S1’ 
pocket, precisely defined "selectivity pocket", because characterized by different shapes 
and geometries among the members of the MMPs family: it is, therefore, objective of 
interest for modulating the selectivity of the inhibitors. 
In particular, three MMPs have been considered important targets in cancer, cardiovascular 
and lung diseases: MMP-8, MMP-9 and MMP-12. MMP-8 is the most potent collagenase 
that degrades collagen type I, which represents the major component of the ECM present 
in the lung. The main disorders with pathological nature are associated with a high degree 
of oxidative stress, where again the activity of MMP-8 is correlated: in fact its plays a 
fundamental role in the activation of reactive oxygen species (ROS) [66-67]. High levels of 
MMP-8 and MMP-9 were found in lung secretions of patients (adults and children) 
suffering from acute forms of lung disease. In asthmatic children it was found that 
eosinophils and macrophages release higher amounts of MMP-8, whereas in healthy 
persons neutrophils are the main source for MMP-8. Sixty percent of lung transplant 
patients develop obliterative bronchiolitis (chronic rejection), in which MMP-8 and MMP-
9 levels are elevated [74]. Many reports the literature [68–69] describe increased MMP-8 
activity during cardiovascular diseases: the serum and plasma MMP-8 concentration is 
correlated with plaque progression and the severity of coronary disease. Moreover, MMP-8 
was demonstrated to be expressed in head and neck squamous carcinoma cells, indicating 
its important role in carcinoma progression [70]. Other diseases such as rheumatoid 
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arthritis [71], gastrointestinal disorders [72] are characterized by altered levels expression 
of MMP-8. [73]. For MMP-9, Rybakoski [75] has analyzed different its involvement as a 
mediator enzyme in cardiovascular disease, cancer and neuropsychiatric disorders. Welsh 
et al [76] have defined a role for MMP-9 in the incidence of coronary arterial disease. 
Further involvement of this metalloprotease was defined in coronary artery disease [77], 
where a high level of MMP-9 expression was detected [78]. In the study by Sakata et al. 
[79] an involvement of this metalloprotease with cancer, has been described. MMP-9 was 
found over-expressed in an epithelial tumour of the ovary with an involvement in lymph 
node metastases of the ovarian carcinoma cells, was found. Instead, the attention to MMP-
12 is due to its involvement in lung inflammation and remodelling [80]: increased levels of 
this metalloproteinase were found in the lung of human patients affected by chronic 
obstructive pulmonary disease (COPD). MMP-12 is the primary elastolytic enzyme of 
alveolar macrophages [81].  A valid intervention for COPD / emphysema patients could 
involve the blocking of MMP-12. Clinical studies on MMP-12 deficient mice showed their 
protection against the development of emphysema induced by cigarette smoke. 
The subject of this thesis has been the study of a way of cellular signalization which 
involves MMPs: the homodimerization process. This is important in signal transduction, 
implicated in many biological processes, both in the homoeostatic regulation and in 
various processes characterized by a pathological nature. To obtaining structural 
information for the design of molecules able to control the signalization pathways, the 
proteins involved will have to be crystallized in complex with ligands that induce 
dimerization. Therefore, in the first part of my thesis’s project I carried out the study of 
protein-inhibitor complexes, testing ligands previously synthesized by the group of Prof. 
Rossello (LC20, LC29 and EN238) on MMP-9 and MMP-12. In the second part of the 
thesis, on the basis of the X-ray results, new inhibitors were designed with the aim of 
increasing the selectivity towards these enzymes. 
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5.1 Crystallographic part 
5.1.1 Introduction 
This crystallographic study has involved MMP-9 and MMP-12 as model system, to study 
the protein dimerization process using synthetic inhibitors. Protein-protein subunit 
interactions play key roles in catalysis and through homo- and heterodimerization events 
act in concert to functionally tune living systems. Among the vast ensemble of possible 
molecular interactions, only a few protein dimerization events serve to modulate biological 
activity. To discover or confirm which interactions are regulatory, various methods can 
contribute in a sequential manner: predictive in silico modeling is a first approach to 
describe the interaction between sites of folded protein subunits for which primary 
sequences are available. An efficient crystallization screening method is important in drug 
design to yield high resolution crystallographic structures of protein-ligand complexes, to 
understand inhibitor selectivity and potency for various members of an enzyme family. The 
strategy used in the following analysis begins with a single condition for each protein-
ligand complex: progressively, more crystallization conditions to obtain the best possible 
crystalline form are tested. 
 
In the technique of X-ray crystallography, the X-rays are diffracted by the crystal form a 
diffraction pattern, from the analysis of this pattern, using the intensities of the reflections 
(diffraction spots) it is possible to obtain the electron density map corresponding to the 
protein contained in the unit cell of the crystal. Because the phases are an unknown 
quantity and need to be “guessed” (probabilistic calculation from heavy atom 
derivatization or from a model believed to resemble the protein in the crystal) at the very 
beginning the map is not very accurate, so it is necessary carry out several cycles of 
refinement with the aid of specific programs that combine general chemical and structural 
knowledge of proteins with the crystallographically acquired data. Among the unknown 
components of the unit cell there is the ligand. To create a restraint file for the 
crystallographic programs to work correctly, the ligand is constructed using the monomer 
library sketcher from CCP4 program. The result is both a restraints file and a coordinates 
file. The coordinates of the ligand are fitted at the binding site on the basis of the electron 
density, using COOT. This first stage is done manually by translating the molecule in the 
electron density and moving each atom in the appropriate place. The initial draft is refined 
using COOT and the ligand restraint file, then the protein and ligand structure is further 
refined with REFMAC5, this completes the first cycle. The model was also improved with 
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refinement cycles in phenix.refine. After each refinement, COOT is used to analyse the 
agreement between the model and the electron density end until an accurate electron 
density map of the ligand-protein complex has been achieved. The final model is used to 
understand the variety of interactions that characterize the specificity of a protein-substrate 
or protein-inhibitor interactions. From this analysis synthetic ligands that fit better the 
topography of the protein catalytic site can be designed characterized so as to achieve 
greater specificity. 
 
5.1.2 Inhibitors tested 
The inhibitors used in the crystallization studies have been: MP24, LC20, LC29, EN238. 
All these ligands were synthesized by the research group of Prof. Rossello
15
. 
 
 LC20 and LC29 are bifunctional ligands (or dual inhibitors) presenting two 
identical arylsulfonamide scaffolds, able to fit in two pockets of the proteins, linked by a 
spacer. These ligands have a different zinc-binding group (ZBG) able to coordinate the 
zinc (II) ion present in the catalytic site of MMPs: a hydroxamic acid for LC29 and a 
carboxylic acid for LC20. 
 EN238 is a mono-ligand: with a single scaffold and a carboxylic acid as ZBG. 
 MP24 is a bifunctional hydroxamate with a scaffold similar to the previous ones 
and a spacer longer than the one present in LC20 and LC29 (MP24 has been previously 
tested by Dr. E. Stura and L.Vera and the results are shown below in order to complete the 
discussion). 
                                                 
15
Associated Professor at the Pharmacy Department of the University of Pisa, Scientific Field of 
Pharmaceutical Chemistry CHIM/08. 
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Depending on the different structure of the inhibitor, the stoichiometry of the ligand and 
the protein used to form the crystals is varied. Ligands bearing two ZBGs and potentially 
able to interact with two proteins simultaneously, have been tested with a 1 inhibitor : 2 
proteins stoichiometry. This stoichiometry facilitates the formation of a homodimeric 
complex in which two molecule of protein are simultaneously inhibited by a single 
molecule inhibitor. Otherwise, ligands with only one ZBG are used with a 1 protein : 1 
inhibitor stoichiometric ratio. In this case the stoichiometry facilitates the formation of a 
monomeric complex in which one ligand molecule interacts with one protein molecule. 
 
5.1.3 Crystallization and structure determination. 
The main difference among all the tested ligands is given by the presence or absence of the 
linker, different lengths and the nature of ZBG. 
Clinical studies have revealed problems of toxicity and poor bioavailability for first and 
second generation hydroxamates. The toxicity problems are attributable to indiscriminate 
binding of these compounds due to the high binding affinity of the hydroxamate group for 
Zn (II) and for other transition metals such as Fe (III), Cu (II) and Ni (II). These metals are 
distributed throughout the body and are also present inside many metalloproteins. 
Hydroxamate based inhibitors bind the zinc ion of various MMPs with poor selectivity 
between family members. This is the main reason why the hydroxamate group, present in 
the vast majority of MMPs inhibitors, give them low therapeutic safety. The carboxylate 
group is therapeutically safer than hydroxamates [41]. 
We have studied whether a linker can confer selectivity to an inhibitor. The linker length 
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influences the flexibility of inhibitors and their adaptability to different pocket proteins. 
The assumption is that the linker needs to be long enough, to allow the correct alignment 
for the two faces of the interacting MMP catalytic domains, without making any steric 
strains with its groups but eventually, providing additional stabilizing interactions in the 
formation of the dimer. Selectivity can be achieved because each protein responds 
differently to the different proposed linkers, irrespective of similar structure of the catalytic 
domain. The linker distance is an important homodimerization parameter that depends on 
inter-protein contacts. Since these interactions are difficult to predict, this parameter is 
difficult to optimize. 
 
 Crystallization of MMP-9·MP24. 
For the crystallization of MMP-9·MP24 complex, the stoichiometry was varied. The 
conditions were: 2 proteins with 1 ligand and in the presence of excess ligand. This 
compound crystallized readily in complex with MMP-9 (Fig.21) but could not be 
crystallized with a MMP-12 homodimer, inspiriting the design of ligands better suited to 
obtain crystals that contained the bi-functional ligand in complex with an MMP-12 dimer. 
 
                                                       a                                                                 b 
Figure 21. a) The MMP-9_MP24 homodimer in the asymmetric unit of PDB entry 4H2E. This MMP-9 
homodimer is very similar to that obtained for compound LC29. b) MMP-9-MP24 monomer (PBD entry 
4H1Q). 
 
An excess of bi-functional ligand, promotes the attachment of one inhibitor per protein 
(PDB entry 4H1Q), where MP24 behaves therefore as a monofunctional ligand, with a 
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resolution to 1.59 Å (Fig.21b). Instead, with a stoichiometric ratio of 2 proteins for 1 
ligand, the formation of a homodimer ensues: one bi-functional inhibitor per protein dimer. 
These crystals diffracted to 2.9 Å (Fig.21a). 
 
 Crystallization of MMP-9·LC20. 
The X-ray analysis from the crystallization of 
MMP-9 with the dual inhibitor LC20, shows the 
formation of a homodimer (Fig.22) with space 
group P21212 (PDB entry 4HMA).The crystals had a 
resolution of 1.94 Å, better than the resolution of 
MMP-9_MP24 homodimer. 
                                                                                                        
 Figure 22. Homodimer of complex MMP-9·LC20. 
 
 Crystallization of MMP-9·LC29. 
The crystallization of this complex has 
been carried out both with and without the 
streak seeding method. In the first case, 
the seeds from the MMP-9-MP24 
homodimeric complex were used. The 
resulting complex crystals diffracted to a 
resolution of 1.9 Å (Fig.23), in space 
group P1 (PDB entry 4H82). Instead, in 
the spontaneously nucleated drop, the 
crystals diffracted to only 2.84 Å. A seed 
has provided a template on which 
additional macromolecules were 
assembled under the proper conditions grow to form a better crystal. Also in this case, 
crystals with a higher resolution than the homodimeric complex MMP-9·MP24, were 
obtained [27]. 
 
 
 
Figura 23: MMP-9-LC29 homodimer diffracted to 
1.9A (PDB entry 4H82). 
 62 
 
 Comparison between the complex of MMP-9·LC29 and MMP-9·MP24. 
The X-ray crystallographic structure of the complex between LC29 and MMP-9 was 
superimposed onto the complex between MP24 and 
MMP-9 (Fig.24). 
 
Figure 24. Superposition of the complex MMP-9·MP24 
(inhibitor in green) in complex with MMP-9·LC29 
(inhibitor in cyan). 
 
The crystal structures show that the bivalent ligands superimposed well into the inhibitor 
part, but this is not valid for the spacer regions. This evidence points out that an alternative 
linker with a shorter spacer, forms the same homo-dimer but with a different geometry as 
expected from its design. Studying the superimposition becomes clearly evident that the 
replacement of the MP24 spacer with a shorter one, gives the correct distance and 
geometry of the twin inhibitor, capable to homo-dimer formation of MMP-9. Indeed, LC29 
with a shorter linker has instead a better affinity than MP24 with a longer linker: 
shortening the length of the linker, the flexibility decreases but at the same time the affinity 
increases. The inhibitor MP24 was crystallized with MMP-9, but no condition has allowed 
the crystallization with MMP-12. This ligand was not properly synthesized for the 
crystallization, but rather with the aim of promoting the design of best ligands, able to 
allow the dimerization of MMP-12. Thanks to the study of the structural problems 
regarding MP24 and its interactions with MMP-9 in both the stoichiometry, it has been 
possible to design other dual inhibitors with shorter linker, compatible with the 
crystallization on MMP-12 and MMP-9. 
 
 Comparison between the complex of MMP-9·LC20 and 
MMP-9·LC29. 
The biological data (reported below) regarding the affinity 
of these two inhibitors and the results from X-rays analysis 
(Fig.25), highlights how the hydroxamic acid (present as 
ZBG) in LC29 is a better chelator, of the zinc ion, compared 
 Figure 25. Superposition of the ligands LC20 and LC29 in their respective complexes with MMP-9, compared 
at the coordination site with the zinc atom of MMP-9. 
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to the carboxylic acid present in LC20. 
 
 MMP-9 complex. 
Both compounds LC20 and LC29 have a shorter linker than the original MP24, these 
ligands are more easily crystallized in complex with MMP-9 and crystals structures at 
atomic resolution have been obtained for both. Similar homodimers mediated by the 
bifunctional ligands are present in the asymmetric unit. None of these spacers impose 
serious restrictions on the formation of MMP-9 homodimers, because of their residual 
flexibility. 
 
 Crystallization of MMP-12·LC20. 
Following the crystallization of this complex in 
space group P212121,, a homodimer, was found in the 
lattice (Fig. 26). In this case, micro-crystals appeared 
spontaneously within a few minutes of mixing the 
protein-inhibitor complex drop with the precipitant 
drop from the reservoir (Fig. 27A). This allowed 
rapid optimization of the crystallization conditions, 
eliminating the needle crystals by controlling the rate 
of nucleation. Several changes in conditions 
crystallization were needed to obtain large crystals. 
Gradually, it was possible to optimize the conditions 
to reproduce larger crystals (Fig.27B). Excessive 
nucleation was controlled by lowering the inhibitor 
concentration. Thus 2 MMP for 1 bi-functional 
ligand was tried and a different crystal form was obtained (Fig.27C). This second crystal 
form is the result of changes in the conditions that improved on initial needles, described in 
Fig.27A [21, 41]. 
 
Figure 26. MMP-12_LC20 complex in 
homodimers structures with P212121 space group 
(PDB entry 4H30). 
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Figure 27. Crystals of MMP-12 complexe with compounds LC20 and EN238. (A) A crystal shower was 
obtained initially. After a few days larger crystals appeared. (B) By refining the reservoir conditions the 
needle shower was avoided and only the prismatic crystals grew spontaneously. (C) The needles were 
improved and the structure determined. The homodimer in the crystal, is identical to that found in the 
prismatic crystals in A and B, but there is a small variation in relative orientation in C and D, with poor 
MMP-12 density for molecule D. (D) Crystals of MMP-12 with mono-functional ligand EN238. 
Morphologically these crystals are similar to those in (B) for ligand LC20. The space groups are the same 
and the cell parameters similar but the packing is different
16
. 
 
Using two different crystallization conditions MMP-12·LC20 complex crystals were 
obtained with same protein (MMP-12 wild type F171D, lot 23.3, 364.5 μM with AHA 10 
mM) and the same inhibitor in two different crystalline forms characterized by two 
different space groups (P21 and P212121), corresponding to different polymorphs (Fig.28). 
 
                                                 
16
Antoni, C.; et al, Crystallization with bi-functional ligands, J. Struct. Biol. 2013, 182, 246-254 [41]. 
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                                      A                                                                               B 
 
Figure 28. Crystal polymorph of MMP12·LC20 complex. A) space group P21, B) space group P212121 . 
 
 Crystallization of MMP-12·LC29. 
In this case LC29 led to the formation of a homodimeric structure (Fig. 29), different from 
that already described for the same protein with LC20. The crystals belong to space group 
P21 (PDB entry 4H49). Both of these inhibitors interact with two protein subunits of 
MMP-12, forming dimers. Affinity measurements with MMP-12 show a greater potency 
for the carboxylate based 
inhibitor than for its 
hydroxamate counterpart, a 
fact never reported before. In 
addition, analyzing the 
hydroxamate group with 
respect to the carboxylate 
one, the ability of the linker 
to induce dimerization, was 
not altered. 
 
 
 
 
 
 
 
  Figura 29. MMP12 in complex with LC29. 
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 Comparison between the complex of MMP-12·LC20 and MMP-12·LC29. 
Both the biological data regarding the affinity of the 
two inhibitors and the results from X-rays analysis, 
highlight how the carboxylic acid (present as ZBG) in 
LC20 is a better chelator of zinc atom compared to the 
hydroxamic acid present in LC29 (Fig.30), where the 
distortion of the LC20 in the dimeric complex leads to 
a closer approach of this group to the zinc, compared 
hydroxamic acid of LC29. This result is noteworthy, 
taking in consideration the side effects associated 
with the use of a hydroxamate group as ZBG.  
 
 
 
 
 Comparison between the MMP-12·LC29 and MMP-9·LC29 complexes. 
In order to study induction of homodimerization also on MMP-12, the crystal structure of 
the complex between LC29 and MMP-9 was 
superimposed to that of LC29 and MMP-12 (Fig. 
31). In this case the semi-rigid linker superimposes 
well in the two structures with the different 
metalloproteins, but it is not able to give the same 
homodimerization. 
 
Figure 31. Superposition of the complexes between LC29 with MMP-9 and MMP12. 
 
 
 
 Crystallization of MMP-12·EN238. 
EN238 is a carboxylic inhibitor designed to provide monomers on MMPs family. Using the 
standard crystallization conditions already defined by Dr. E. Stura and L.Vera to obtain 
MMP-12 complex [12, 27] crystals appeared after few minutes and seeding was not 
necessary. Afterwards, by working out the electron density map, it was possible to see that 
the monomeric inhibitor led to a homodimer formation in the P212121 asymmetric unit, 
behaving not as a simple monomer, as hypothesized (Fig.32-B). EN238 favoured the 
Figure 30. Superposition of the 
ligands LC20 and LC29 in their 
respective complexes with MMP-12, 
compared to the coordination with the 
zinc atom of the metalloproteinase. 
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formation of a dimer through specific interactions contributed by each individual inhibitor, 
and each protein subunit of the homodimer (PDB entry 4H84). 
 
                                      a                                                                               b 
Figure 32. (a) Chemical structure of compound LC20 and packing of the MMP-12 induced homodimer in 
space group P212121. (b) Chemical structure of compound EN238 and MMP-12 homodimer formed with 
compound EN238 in the same space group, P212121. This MMP-12 homodimer is different from that formed 
with compound LC20. 
 
 Comparison between the complexes of MMP-12·LC20 and MMP-12·EN238 
Data from crystals of the MMP-12·EN238 complex, 
have similar cell parameters, but not identical to those 
for the MMP-12·LC20 complex. Observing the 
superposition of MMP-12 bound to the 
monofunctional and bifunctional ligands, it is possible 
to see that the positioning of the mono-functional 
ligand matches that for the bi-functional one (Fig.33) 
except regarding the homodimerization mode 
(Fig.32a-b). It may therefore be hypothesized that 
MMP-12 imposes strong constraints on ligand 
Figure 33. Superposition of MMP-12 bound to compounds LC20 and EN238,  
showing good superposition for the ligands. 
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positioning, influencing dimerization. In this study of the interaction between a protein 
and a dual inhibitor, whose ends are joined together by a central linker, dimerization 
can be affected by the presence of a more or less rigid structure, and when compared 
with a monovalent ligand by the sole presence of a linker. Comparing mono-functional 
EN238 with the bi-functional LC20, the mono-functional allows greater flexibility, 
even if due to a certain structural rigidity it can also induce formation of some 
homodimers. This limitation could then be used as a variable to deliberately select a 
defined homodimeric conformation and eliminate unwanted lattice polymorphism. In 
the homodimer with EN238, the phenyl of the half-linker makes van der Waals 
interactions within a hydrophobic pocket of the second molecule that composes the 
MMP-12 dimer in the asymmetric unit. 
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5.2 Chemical synthesis section 
5.2.1 Design and synthesis. 
Initial crystallographic studies conducted on ligands previously synthesized in the 
laboratory of Prof. Rossello, such as MP24, LC20, LC29, EN238, have allowed to acquire 
the necessary knowledge for the design of new inhibitors. The vision of the real positioning 
of these ligands, within the pocket of a MMP, has turned the study towards the design of 
selective inhibitors in which the sulfonamidic scaffold is at the basis of the new 
compounds structure.  
 
 The first objective was to design and synthesize a new dual carboxylate inhibitor, 
SA001, based on the spontaneously formed dimer obtained between two molecules of 
EN238 with two molecules of MMP-12, with space group P212121 (Fig.32b). The aim 
was to insert a linker between the two molecules of EN238 so as to encourage the 
formation of this homodimer even in presence of the resultant dual inhibitor. The 
structure of SA001 was designed by using programs like COOT and CCP4, as 
previously explained, which allowed the insertion of the linker in the electron density 
map of the complex EN238·MMP-12. Superimposing the draft of the inhibitor onto the 
two molecules of EN238 (oriented according to the arrangement dictated by the dimer) 
structural changes were progressively operated on the new bifunctional ligand. The 
isopropyl of the original structure of EN238 was removed because, with the insertion 
of the linker in the new structure, its orientation was changed (if compared to its 
original position) and the new distances, previously optimal for the interaction with the 
various boundary amino acids, could cause steric hindrance. Adjustments for achieving 
the optimal length of the linker were developed with the intent to reproduce precisely 
the same dimer spontaneously formed with the mono-ligand, suggesting to choose a 
linker with three carbon atoms. Particular functional groups have not been added on the 
spacer because the initial assumption was to understand the regulatory mechanism of 
the dimer formation and therefore we have chosen a spacer with a relatively simple 
structure (Synthesis in Scheme 1). 
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 A further objective was to synthesize the hydroxamate analogue of EN238 (LR32): it 
has a hydroxamate group as ZBG, in place of the initial carboxylic acid, in order to 
compare the different affinities of these two ligands for the MMPs. In addition, a 
further point to test would have been to verify if this derivative was able to form the 
same dimer as EN238 with MMP-12 (Synthesis in Scheme 4). 
                                                       
 
 Finally, the synthesis of two dual inhibitors (CA11 and CA14) with a short ureidic 
linker was planned. These had the same sulfonamidic scaffold but a different ZBG 
(carboxylate and hydroxamate, respectively). The purpose of the synthesis of these 
inhibitors, was to directly evaluate how the length of the linker could affect the 
mechanism of homodimer formation among MMPs family members. (Synthesis in 
Schemes 4-5). 
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Scheme 1 shows the retrosynthetic analysis of SA001.  
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Scheme 1  
The fundamental synthon was represented by the diamide A which could be easily 
obtained starting from 2,6-diaminopimelic acid (DAP, 1) in two steps, as reported in 
Scheme 2. 
 
 
 
 
Scheme 2 
 
Our first attempts to obtain diamide A (compound 3 in Scheme 2) according to this route 
gave disappointing results, mostly due to the low yield and poor reproducibility of the 
amidation step using aqueous ammonia solution (33%). Therefore, with the aim to improve 
the synthetic process of SA001, we decided to follow the alternative route described in 
Scheme 3. 
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 Scheme 3  
Diamide A (3) was obtained starting from DAP, 1, in three steps with high overall yield. 1 
was first converted into methyl ester 4 by treatment with thionyl chloride in MeOH, then 
N-acylated with benzoyl chloride to give ester 5, which was finally converted into diamide 
3 by ammonolysis with dry ammonia gas. Selective reduction of primary amide groups of 
3 with lithium borohydride (LiBH4) and MeOH in THF provided the corresponding 
diamine 6 in good yield, as mixture of two diastereomers. The synthesis was stopped at 
compound 6, due to thesis timing and the concomitant other activities linked to the 
synthesis of the other new dimeric inhibitors (see synthetic Schemes 4 and 5 for LR32, 
CA11, CA14 and CA15) 
 
Hydroxamic acid LR32 was prepared as shown in Scheme 4.  
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Scheme 4  
Compound 8 has been previously synthesized in the laboratory of Prof. Rossello: the 
carboxylate group was protected as tert-butyl ester by treatment with N,N-
dimethylformamide di-tert-butyl acetal. Sulfonamide 9 underwent Mitsunobu 
condensation, in the presence of diisopropylazodicarboxylate (DIAD) and 
triphenylphophine, with alcohol 10 to give the ester 11. The latter was subsequently 
subjected to selective hydrolysis in presence of trifluoroacetic acid (TFA) to remove the 
NH-Boc protection. Tert-butyl ester 13 was obtained by acylation of 12 with benzoyl 
chloride, using N,N-diisopropylethylamine (DIPEA) as base. Acid cleavage of ester 13 
yielded carboxylate 14 which was finally converted to its corresponding hydroxamate 
LR32 by condensation with O-(tert-butyldimethylsilyl)hydroxylamine followed by acid 
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hydrolysis with TFA. 
The dual inhibitors CA11 and CA14 were prepared as shown in Scheme 5.  
 
 
 
 
 
Scheme 5 
Compound 12 was treated with 1,1 '-carbonyldiimidazole (CDI) leading to the formation of 
the desired di-tert-butylester, 16, and the secondary product 17. After their separation and 
purification by flash chromatography, both these two esters underwent the same process of 
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hydrolysis in presence of TFA, thus providing the di-carboxylic acids CA11 and CA15, 
respectively. CA11 was then reacted with O-(tert-butyldimethylsilyl)hydroxylamine in the 
presence of 1-[3-(Dimethylamino)propyl]-3-ethyl carbodiimide hydrochloride (EDC) as 
condensing agent, obtaining the cyclic intermediate 18 as principal product instead of the 
expected di-sylilether. Since the unexpected product was thought to be interesting to be 
tested and crystallized, 18 was subjected to the mono-silylether hydrolysis with TFA to 
give the mono-hydroxamate CA14_2. 
 
5.3 Crystallographic investigations of CA11, CA14_2, CA15 binding. 
The derivatives listed above have been crystallized in complex with MMPs. These 
inhibitors were tested on MMP-8, MMP-9, MMP-12 by Dr. Stura and L. Vera 
 
 Preliminary X-ray results on CA11. 
 CA11·MMP-8 complex. 
Although CA11 has two ZBG and could 
potentially promote dimer formation, CA11 
can also bind as a monomer on the MMP-8 
(Fig.34). During crystallization trials both 1:1 
and 1:2 inhibitor:MMP ratios are tested but 
obtaining crystals with both requires several 
attempts and optimization. The figure shows 
monovalent binding where one of the two 
biphenyl sulfonamidic scaffolds penetrates 
into the pocket of the protein and only one of 
the two carboxylic acids interacts with the zinc 
ion of MMP-8.   
 
 
 
 
 
 
 
Figure 34 X-ray structure of the 
CA11∙MMP-8 complex. 
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 Crystallographic CA11·MMP-9 complex. 
CA11 is a dual inhibitor. 
Crystals were obtained for the  
homodimeric complex with 
MMP-9 (Fig.35). This 
complex was then compared 
with other complexes formed 
between CA11 with MMP-8 
and MMP-12, discussed 
below.  
Figure 35. X-ray structure of the CA11·MMP9 complex. 
 
 CA11_MMP-12 complex. 
CA11 can induce a homodimeric MMP-12 complex that is different that previously 
obtained with the bi-functional inhibitor LC20. 
 
a                                                         b 
Figure 36. a) X-ray structure of CA11_MMP12 complex; b) superimposition of CA11 (blue) and 
LC20 (orange) in their complex with MMP-12. 
 
The superposition of the CA11∙MMP-12 and LC20∙MMP-12 homodimers (Fig 36-
b) clearly shows the different spatial arrangements adopted by the enzyme in the 
two complexes. The two homodimers are adopting two different orientations 
relative to each other although the linkers are only slightly staggered. This suggests 
that linkers shorter than LC20 (11 atoms in total) cannot maintain the same 
homodimerization mode. Linkers similar as the length of CA11 (with 7 atoms in 
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total) still allow MMP-12 homodimerization. Homodimeric interactions, different 
for each MMP, can contribute to increase the selectivity of the inhibitor in favor of 
MMP-12 (biological data given below). 
 
 Comparison of complexes obtained with CA11. 
Thanks to the superimposition of the images relating to X-ray of the complexes 
above, it is possible to compare the different positions adopted by CA11 in complex 
with MMP-8, MMP-9 and MMP-12 (Fig.37). 
Both crystallographic complexes of MMP-12 and 
MMP-9 with the inhibitor CA11 are homodimers 
while monomeric binding for MMP-8 was 
observed. In the homodimeric complexes CA11 
superimposes almost exactly on itself in the 
MMP-12 and MMP-9 complexes. In both cases, 
it promotes the formation of homodimers, but the 
intermolecular orientations of the two proteinases 
is different in the two cases. In the MMP-8 
complex only the monomeric binding was 
analysed. The orientation of CA11 shows 
flexibility: one sulfonamidic scaffold overlaps the 
other two, whereas the second one is redirected towards a secondary pocket on the 
proteinase. 
 
 Preliminary X-ray results on CA14_2. 
CA14_2 was tested with MMP-12, MMP-9, MMP-8, but so far crystals have been 
obtained only in complex with MMP-8. 
 
 CA14∙2MMP8 complex. 
The X-ray crystallography structure shows a dimer. In addition to protein-protein 
interactions, the formation of the homodimer is also mediated by interactions that 
are established directly between the two molecules of inhibitor (Fig. 38A-B).  
Figure 37. CA11 overlapping in 
different complexes with MMP-12 
(blue), MMP-9 (green), MMP-8 
(yellow). 
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a                                                            b 
Figure 38. a) X-ray image of MMP-8∙CA14 complex; b) Interaction between the two molecules of 
CA14, in the complex MMP-8∙CA14. 
 
The analysis of the interactions established between the two molecules of inhibitor 
aiding to form the MMP-8 homodimer suggest new ways to design selective 
inhibitors for this metalloprotease. 
 Preliminary X-ray results of CA15. 
CA15 was used for crystallographic trials with MMP-12, MMP-9, MMP-8, providing 
at the moment a complex exclusively with MMP-8. 
 
 CA15∙MMP-8 complex. 
CA15 has been crystallized with MMP-8 as a monomeric complex (Fig.39).  In this 
case, the shortening of the linker up to 5 atoms in total, has not resulted in the  
 
formation of a homodimer between the metalloproteases analyzed. Further 
crystallization trials may result in crystal with a dimer the lattice.                                                                
Figure 39. 
a) Monomeric complex between 
CA15∙MMP-8;  
 b) Interaction of the carboxylic 
acid with the zinc of the MMP-8. 
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5.4 Biological data of CA11, CA14_2, CA15. 
All the new inhibitors were tested in vitro on human recombinant MMPs (MMP-1, MMP-
2, MMP-8, MMP-9, MMP-12, MMP-13, MMP-14) by fluorometric assay. Results are 
reported in Table 1, together with those obtained for the previously synthesized analogues 
(EN238, LC20 and LC29).     
 
Table 1. In vitro activity (IC50, nM) on MMPs. 
Compd MMP9 MMP12 MMP1 MMP2 MMP8 MMP13 MMP14 
EN238 508 35 16000 170 115 152 1830 
LR32 2.5 1.5 13 0.16 2.0 0.24 23 
LC20 26 1.3 11800 63 89 35 2200 
LC29 5.5 7.1 280 10 8.9 8.2 250 
CA11 175 4.6 8300 145 134 200 1700 
CA14_2 26 15 3100 42 15 9 4900 
CA15 430 22 17000 460 116 420 8900 
 
All compounds showed a nanomolar activity against MMP-9 and MMP-12. In general, 
carboxylates were characterized by a higher selectivity for these proteases over the other 
MMPs with respect to the corresponding hydroxamates. In fact, hydroxamates such as 
LR32, LC29 and CA14_2 resulted powerful but unselective MMPs inhibitors. Comparing 
carboxylate dual-inhibitors with the corresponding monovalent derivatives (i. e. LC20 with 
EN238) highlights the importance of having a dual ligand. In fact, LC20 displayed an 
improved activity and selectivity for MMP-12 and MMP-9 with respect to EN238. The 
newly synthesized carboxylate dual-inhibitor CA11 showed a drop of activity against all 
tested MMPs with respect to LC20, probably due to the shorter linker. Finally, the mono-
hydroxamate cyclic derivative CA14_2 resulted poorly selective like all the other 
hydroxamates and about 10 times less active than LC20 on MMP-12. Further information 
about the biological activity of these dual MMPs inhibitors will be provided by cell assays 
on gliomas that are currently ongoing in Prof. Martini's laboratory. 
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Chapter VI 
EXPERIMENTAL PROCEDURES 
 
6.1 Crystallization procedures. 
The crystallization experiments were conducted under the supervision of Dr. Stura, in the 
research laboratory of the CEA, iBiTec-S, Service d’ Ingénierie Moléculaire des Protéines 
(SIMOPRO), Gif-sur-Yvette, France. 
 
6.1.1 Material and Methods. 
The MMPs were prepared and purified by E. Lajeunesse and L.Vera. The inhibitors MP24, 
EN238, LC20, LC29 were synthesized by the research group of Prof. Rossello. The 
CrysChem sitting drops plates were used for loading the crystallization experimets. The 
plates were kept at constant temperature of 20 °C, in a thermostat. The precipitant and 
cryoprotective solutions used were part of the L. Vera and Dr. Stura’s kit [12]. The data 
were collected at the Soleil synchrotron Facility (St. Aubin, France) on beamline Proxima 
1 (at 100 K from a single crystal and reduced using XDS and the script “xdsme”) and at the 
European Synchrotron Radiation Facility (ESRF) in Grenoble (France), on beam line 
ID23–1 (the data processed automatically using XDS). The structure was solved by rigid 
body refinement using REFMAC5. The inhibitor was built using the monomer library 
sketcher from CCP4 program suite the model was subsequently optimized with cycles in 
COOT, followed by cycles of REFMAC5. The structure was solved by molecular 
replacement using MOLREP. The ligand prepared with the sketcher, the restraints prepared 
with phenix.elbow and positioned in the binding site with COOT. The model was improved 
with cycles in phenix.refine and COOT. 
 
6.1.2 Crystallization experiments. 
Crystallization experiments were carried out in CrysChem sitting drop vapor diffusion 
plates (Fig.15). A volume of 6 μL of protein sample is mixed to a precise volume of 
inhibitor, defined by the stoichiometry used: 1 μL of the mix is used for single drop. The 
drop, generally, was composed by 1 μL of protein-inhibitor solution and 1 μL of precipitant 
solution, taken directly from the reservoir. At this point it is necessary to isolate the 
experiment from the external environment sealing it with a coverslip. A stoichiometry of 1 
protein for 1 ligand was used for monofunctional inhibitors (EN238), whereas a 
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stoichiometry of 2 proteins per ligand was usual for dual inhibitors (LC20, LC29). At the 
very beginning, the screenings of MMP-9 and MMP-12 were based on pre-established 
crystallization conditions determined by Dr. E. Stura
17
 and L. Vera
18
. The availability of 
efficient crystallization conditions, made the initial process faster. Using this information it 
was possible to optimize the yield of crystals. Afterward, new specific strategies were 
developed. For MMP-9, crystal needles were introduced immediately to facilitate the 
selection of the optimal working conditions, by streak seeding. This procedure is carried 
out within 10 minutes after the deposition of the drops of protein-ligand solution and the 
precipitant solution: after, the coverslip was sealed. The vapor diffusion trays were stored 
in a cooled incubator at 20°C. For X-ray data collection, the crystals were harvested with a 
cryo-loop and transferred to a cryo-protective solution and then rapidly plunged in liquid 
nitrogen to cryo-cool the crystals. [11]. 
 
6.1.3 Crystals of MMP-9∙inhibitor complex. 
The MMP-9∙E219Q mutant [11] where the catalytic glutamate is mutated to glutamine was 
used in these experiments. At the beginning, similar conditions for all inhibitors were 
tested: 14% PEG 20K, 100 mM PCTP 75/25 [sodium propionate, sodium cacodylate, bis-
tris-propane (component A pH 4; component B pH 9.5)], 1 M NaCl in 500 μL of reservoir 
solution. 
 Drops were composed by 1μL of protein and 1μL of precipitant solution. A few days later 
the first crystals appeared [41]. 
 MMP-9∙LC29: Small crystals of rectangular shape were obtained and no protein 
precipitation in the drop was observed. The precipitant solution was composed of 10% 
PEG 20000, 100 mM PCTP 75/25, 1.5 M NaCl in 500 μL of reservoir volume. The 
structure resolution was 1.9 Å (PDB code 4H82) [Fig.23]. Instead, a condition of 12% 
PEG 20000, 100 mM PCTP 75/25, 1.5 M NaCl in 500 μL gave larger crystals, rectangular 
in shape and some precipitate. 
 MMP-9∙LC20: In 12% PEG 20000, 100 mM PCTP 75/25, 1.5 M NaCl in 500 μL 
of reservoir volume, larger crystals with rectangular shape were formed [Fig.22]. Instead, 
                                                 
17
Researchers at CEA, iBiTec-S, Service d’Ingénierie Moléculaire des Protéines (SIMOPRO), Gif-sur-
Yvette, France. 
18
Superior technician at CEA, iBiTec-S, Service d’Ingénierie Moléculaire des Protéines (SIMOPRO), Gif-
sur-Yvette, France. 
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composition of 10% M PEG 20000, 100mM PCTP 75/25, 1.5M NaCl in 500 μL of 
reservoir volume allowed the formation of many smaller crystals. 
 MMP-9∙EN238: Crystals formed spontaneously without the need for seeding with 
a reservoir solution of 12% PEG 20,000, 140 mM imidazole malate, 175 mM NaCl, pH 8.5 
6.1.4 Crystals of MMP-12-inhibitor complex. 
The MMP-12 wild type was used in these experiments. 
 MMP-12∙LC20: For this crystallization, seeding was not necessary, because the 
first microcrystals appeared spontaneously on the first attempt. The initial precipitant 
solution was composed by 17% PEG 20000, 200 mM imidazole malate pH 8.5, 250 mM 
NaCl : the volume ratio used was 1μL of precipitant solution and 1μL of protein-inhibitor 
solution. Few minutes later, microcrystals appeared and a few hours afterward, smalls thin 
needles came out (Fig.27A). 
The concentration of precipitant solution was changed to increase the crystals 
dimension and to try to control the excessive nucleation to 3% PEG 20000, 200 
mM imidazole malate pH 8.5, 50 mM NaCl. This condition was better than the 
previous one because the needle shower formation has been avoided and only  
prismatic crystals grew spontaneously (Fig.27B). The resolution achieved was 
1.42 Å (PDB code 4H30). 
Several changes were tried, such as a different volume ratio of mix protein-
inhibitor solution and the composition of the working solution: in particular, 
other different crystals form, using 2 μL of MMP-inhibitor solution added to 
0.5μL of precipitant solution, was obtained (Fig.27C). 
Crystals obtained for the MMP-12∙EN238 complex (Fig.27D) are 
morphologically very similar to those one of the MMP-12∙LC20 complex 
(Fig.27B): the space group is the same, but the packing is different. (Fig.27D). 
 MMP-12_LC29: the first solutions were composed by progressive dilution of a 
specific working solution, usually used for MMP-12. Dilutions were used at 40%, 30%, of 
a solution composed by: 17% PEG 20000, 200 mM imidazole malate pH 7.5, 250 mM 
NaCl. However, all the drops showed small needles. Therefore, the pH of the precipitant 
solution was changed: a new precipitant solution composed by 17% PEG 20000, 0.2 M 
imidazole malate pH 6.0, 250 mM NaCl was able to give crystals in form of lamellae 
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diffracting to 2.16 Å resolution (PDB code 4H49). 
 MMP-12_EN238; In this case, seeding was not needed as the selected 
crystallization conditions typically used with MMP-12 gave after few minutes crystals of 
this complex spontaneously nucleated (Fig. 27D). Initially, a specific MMP-12 precipitant 
solution was tried: 17% PEG 20K, 0.2M imidazole malate pH 8.5, 250mM NaCl. This 
condition showed smalls square crystals. Subsequently, a dilution of 70% of this mix 
solution was lead to bigger crystals. A volume of 50 μL, 5 M NaCl was added to the 500 
μL reservoir to allow a better crystals growth, by slowly increase the removing of water 
vapor, accelerating crystal growth (Fig. 32B). 
 
6.1.5 Cryo-protectant condition. 
The freezing of crystals represents a very delicate stage in the diffraction experiment 
preparation process. The main cryo-protectant condition used, were: 
 Cryo-solution MMP-12 _LC20 complex: 27% PEG 8000, 15% MPEG 550, 10% 
glycerol, 90mM Tris-HCl, pH 8.5. 
 Cryo-solution MMP-12_LC29 complex: 10% di-ethylene glycol, 10 % glycerol, 10 
% 1,2- propanediol, 25% M PEG 5000, 100mM BES pH 5.5. 
 Cryo-solution MMP-12_EN238 complex: 5% Di-ethylene glycol, 10% 1,2-
propanediol, 5% glycerol, 5% ethylene glycol, 5% DMSO, 9% PEG 10000, 100mM MMT 
buffer 75/25 (L-malic acid, 75% component A, pH 4;  25% component B, pH 9), 1 M 
NaCl. 
 Cryo-solution MMP-9_LC29 complex: 10 % di-ethylene glycol, 10 % 1.2- 
propanediol, 10% glycerol, 1.5 M NaCl, 100 mM PCTP buffer 80/20, 9% PEG 10,000. 
The cryoprotection conditions for the crystals reported in this work, were determined by 
Dr. Stura and L. Vera. A total between 200 and 1000 images for each crystal, were 
collected during the analysis. 
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6.2 Chemistry experiments. 
The chemistry experiments were conducted under the supervision of Dr. E. Nuti and Prof. 
A. Rossello, in the laboratory of the Dipartimento di Farmacia,  niversit  di Pisa, Pisa, 
Italy. 
 
6.2.1 Materials and Methods. 
Melting points were determined on a Kofler hotstage apparatus and are uncorrected. 
1
H 
and 
13
C NMR spectra were determined with a Varian Gemini 200 MHz spectrometer. 
Chemical shift (δ) are reported in ppm and J in Hz. The following abbreviations were used 
to explain the multiplicities: s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet, 
dt=double triplet, dd=double doublet. Evaporation was performed under vacuum 
conditions in rotating evaporator. Chromatographic separations were performed on silica 
gel columns by flash column chromatography (Kieselgel 40, 0.040–0.063 mm; Merck) or 
using ISOLUTE Flash Si II cartridges (Biotage). Reactions were followed by thin-layer 
chromatography (TLC) on Merck aluminum silica gel (60 F254) sheets that were 
visualized under a UV lamp and hydroxamic acids were visualized with FeCl3 aqueous 
solution. Anhydrous sodium sulfate was always used as the drying agent. Yields refer to 
isolated and purified products. 
 
6.2.2 Synthesis 
Synthesis of 2,6-bis(benzamido)heptanedioic acid (2). 
2,6-Diaminopimelic acid 1 (5.26 mmol, 1 g) was dissolved in H2O (8 mL) and the solution 
was cooled to 0 °C. NaOH (21.04 mmol, 0.8415 g) was added to the solution under 
magnetic stirring. Benzoyl chloride (10.52mmol, 1.22 mL) in Et2O (8 mL) was added to 
the reaction kept at 0 °C. The mixture was stirred overnight at RT. The reaction mixture 
was diluted with Et2O (3 mL) and H2O (3 mL), and the H2O was separated. The water 
phase was acidified with 1N HCl (10 mL), until formation of a white solid. This precipitate 
was extracted with AcOEt (200 mL) and the organic phase was washed with brine (50 mL) 
and dried over Na2SO4. The solvent was evaporated to yield the desired carboxylic acid 2 
(0.34 g) as a white crystalline solid. 
Yield: 93% 
1
H-NMR (DMSO) δ: 1.40-1.60 (m, 2H); 1.72-1.95 (m, 4H); 4.31-4.39 (m, 2H); 7.40-7.54 
(m, 6H); 7.84-7.88 (m, 4H); 8.59 (dd, J1=7.7 Hz, J2=2.9 Hz, 2H). 
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Synthesis of 2,6-bis(benzamido)heptanediamide 3 (A)
19
. 
EDC (6.80 mmol,1.30 g) was added under magnetic stirring to a dioxane solution (34 mL) 
of compound 2 (3.40 mmol, 1.35 g) and N-hydroxysuccinimide (6.80 mmol, 0.78 g). The 
reaction was kept under stirring for 1 h and the white precipitate was filtered off. NH4OH 
33% solution (27 mL) was added to the filtrate and the magnetic stirring was maintained 
overnight. The solvent was evaporated to yield a yellow powder. This precipitate was 
extracted with AcOEt (250 mL), resulting partially soluble: the organic phase was washed 
with brine (100 mL) but not dried over Na2SO4, given the presence of a suspension. The 
solvent was evaporated to yield 3 as white-yellow solid (1.11g). 
Yield: 33% 
1
H-NMR (MeOD) δ: 1.55-1.65 (m, 2H); 1.85-1.97 (m, 4H); 4.57 (t, J=6.9 Hz, 2H); 7.39-
7.52 (m, 6H); 7.77-7.84 (m, 4H).  
 
 
6.2.2 Synthesis of 2, 2' - (( 2, 6 – bis (benzamido) heptanes - 1, 7 – diyl) bis (([ 1, 1' – 
biphenyl ] - 4 - ylsulfonyl ) azanediyl ))diacetic acid (Scheme 3, compound 6). 
 
Synthesis of 1,7-dimethoxy-1,7-dioxoheptane-2,6-diaminium chloride (4)
20
. 
2,6-Diaminopimelic acid 1 (5.26 mmol, 1 g) was dissolved in MeOH (8.4 mL), under N2. 
The suspension was cooled to -5 to -10 °C (ice/acetone bath) and treated dropwise with 
thionyl chloride (11.57 mmol, 0.85 mL). The mixture was stirred at -5 to -10 °C for 1h, 
then overnight at room temperature, when TLC monitoring (CHCl3/MeOH/NH4OH, 4:8:1), 
indicated completion of the reaction. The solvent was evaporated to yield the amino ester 4 
(1.53 g) as white solid.  
Yield: 99% 
1
H-NMR (DMSO) δ: 1.35-1.60 (m, 2H); 1.70-1.85 (m, 4H); 3.74 (s, 6H); 3.94-4.05 (m, 
2H); 8.73 (s, 6H).  
 
Synthesis of dimethyl 2,6-bis(benzamido)heptanedioate (5). 
                                                 
19
 C. Exon, T. Gallagher, P. Magnus. Indole-2,3-quinodimethanes: A new Strategy for the Synthesis of 
Tetracyclic Systems of Indole Alkaloids. J. Am. Chem. SOC., I983, 105, 4739-4749 [65]. 
20
 M. Ilies, L. Di Costanzo, M. L. North, J. A. Scott, D. W. Christianson. 2-Aminoimidazole Amino Acids as 
Inhibitors of the Binuclear Manganese Metalloenzyme Human Arginase I. J. Med. Chem. 2010, 53, 4266–
4276,[56]. 
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The ester 4 (2.58 mmol, 0.750 g) was dissolved in H2O (6 mL) and the solution was cooled 
to 0 °C. To the solution was added NaOH (10.32 mmol, 0.413 g), maintaining the stirring. 
Benzoyl chloride (5.16 mmol, 0.60 mL) was dissolved in Et2O (6 mL), and this solution 
was added to the previous, at 0 °C. The mixture was stirred overnight at RT. The reaction 
mixture was diluted with EtOAc (100 mL), and separated water. The organic phase was 
washed once with a saturated solution of NaHCO3 (40 mL) and once with brine (40 mL) 
and dried over Na2SO4. The solvent was evaporated to give 5 as a yellow crystalline solid 
(383 mg). 
Yield: 35% 
1
H-NMR (CDCl3) δ: 1.51-1.68 (m, 2H); 1.82-2.03 (m, 4H); 3.73 (s, 3H); 3.75 (s, 3H); 
4.69-4.85 (m, 2H); 6.96 (d, J=8.0 Hz, 1H); 7.01 (d, J=8.0 Hz, 1H); 7.29-7.54 (m, 6H); 
7.73-7.85 (m, 4H).  
 
Synthesis of 2,6-bis(benzamido)heptanediamide (3)
21
. 
Dry ammonia gas was bubbled for 20 min into a solution containing the methyl ester 5 
(0.89 mmol, 0.38 g) and glycerol (4.4 g) in MeOH (15 mL) at 4 °C. Dry ammonia gas was 
obtained by dropping NH4OH 33% solution (10 mL) on KOH solid (4 g). The vial was 
tightly closed and left at RT overnight. MeOH and ammonia were removed by evaporation 
and the residual liquid was dissolved in water (80 mL). After acidification with 1N HCl, 
the solution was extracted with EtOAc (2x150 mL). The combined organic layers were 
washed with brine (2x50 mL). The solvent was evaporated to yield diamide 3 as white 
crystalline solid (0.34 g). 
Yield: 96% 
1
H-NMR (MeOD) δ: 1.55-1.65 (m, 2H); 1.85-1.97 (m, 4H); 4.57 (t, J=6.9 Hz, 2H); 7.39-
7.52 (m, 6H); 7.77-7.84 (m, 4H).  
 
Synthesis of N,N'-(1,7-diaminoheptane-2,6-diyl)dibenzamide (6)
22
. 
To a solution of amide 3 (0.605 mmol, 0.240 g) and LiBH4 (3.63 mmol, 0.079 g) in 
                                                 
21
 Y. Yamazaki, M. Savva, H. K. Kleinman, S. Oka, M. Mokotoff. Enhanced cleavage of diaminopimelate - 
containing isopeptides by leucine aminopeptidase and matrix metalloproteinases in tumors: application to 
bioadhesive peptides. J. Peptide Res., 1999, 53, 177-187 [61]. 
22
 K.Soai, A.Ookawa. Mixed Solvents Containing Methanol as Useful Reaction Media for Unique 
Chemoselective Reductions with Lithium Borohydride. J. Org. Chem. 1986, 51, 4000-4005 [62]. 
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THF(2.5 mL), was added MeOH (0.3 mL). The mixture was refluxed for 4h, under Argon. 
After quenching the reaction by adding MeOH, was added oxalic acid (0.726 mmol, 0.065 
g). The solvent was evaporated under reduced pressure and the crude was purified by flash 
chromatography to obtain di-amine 6 as a mixture of two diastereomers. 
Chromatographic conditions: Eluent CHCl3 20 : 1 MeOH. Flash column: h = 21 cm; d = 
3 cm. 
Yield: 49% 
1
H-NMR (MeOD) δ: 1.20-1.49 (m, 6H); 3.30 (d, J=5.8 Hz, 4H); 3.78-3.84 (m, 2H); 7.05-
7.23 (m, 6H); 7.46-7.52 (m, 4H).  
 
 
6.2.3 Synthesis (R)-N-(2-(N-(1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-[1,1'-biphenyl]-
4-ylsulfonamido)ethyl)benzamide (Scheme 4, compound LR32). 
 
Synthesis of (R)-tert-butyl 2-([1,1'-biphenyl]-4-ylsulfonamido)-3-methylbutanoate (9). 
A solution of carboxylic acid 8 (7.85 mmol, 2.62 g) in anhydrous toluene (15 mL) 
containing N,N-dimethylformamide di-tert-butyl acetal (31.4 mmol, 7.53 mL) was heated 
to 95 ºC for 3 h. The solvent was then evaporated and the crude product was purified by 
flash chromatography on silica gel (n-hexane/EtOAc 4:1) to give 9 as a white solid. 
Yield: 44% 
1
H-NMR (CDCl3) δ: 0.86 (d, J= 6.7 Hz, 3H); 1.02 (d, J= 6.7 Hz, 3H); 1.19 (s, 9H); 1.98-
2.14 (m, 1H); 3.63-3.70 (dd, J= 4.6 Hz, J= 10.0 Hz, 1H); 5.15 (d, J= 9.8 Hz, 1H); 7.41-
7.58 (m, 5H); 7.66-7.70 (m, 2H); 7.88-7.92 (m, 2H). 
 
Synthesis of (R)-tert-butyl 2-(N-(2-((tert-butoxycarbonyl)amino)ethyl)-[1,1'-biphenyl]-4-
ylsulfonamido)-3-methylbutanoate (11). 
Diisopropyl azodicarboxylate (DIAD) (4.39 mmol, 0.864 mL) was added dropwise to a 
solution containing the alcohol 10 (1.26 mmol, 0.20 g), the sulfonamide 9 (1.88 mmol, 
0.733 g) and triphenylphosphine (4.39 mmol, 1.152 g) in anhydrous THF (21 mL) under 
argon atmosphere at 0 ºC. The resulting solution was stirred overnight at RT and 
evaporated under reduced pressure to afford a crude product, which was purified by flash 
chromatography on silica gel (n-hexane/EtOAc 8:1) (Rf= 0.3) to yield 11 as a yellow oil. 
Yield: 76% 
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1
H-NMR (CDCl3) δ: 0.92 (d, J=6.4 Hz, 6H); 1.04 (d, J= 6.4 Hz , 3H); 1.22 (s, 9H); 1.41 
(s, 9H); 2.01-2.17 (m, 1H); 3.22-3.46 (m, 3H); 3.73-3.83 (m, 1H); 3.96 (d, J= 9.6 Hz, 1H); 
5.15 (t, 1H); 7.38-7.56 (m, 5H); 7.64-7.68 (m, 2H); 7.87-7.91 (m, 2H). 
13
C-NMR (CDCl3) 
δ: 19.34; 20.07; 27.83; 28.47; 29.30; 41.30; 44.73; 66.69; 79.19; 82.05; 127.25; 127.61; 
128.08; 128.47; 129.05; 183.34; 189.28; 145.60; 155.83; 169.60. 
 
Synthesis of (R)-tert-butyl 2-(N-(2-aminoethyl)-[1,1'-biphenyl]-4-ylsulfonamido)-3-
methylbutanoate (12). 
Trifluoroacetic acid (57 mmol, 4.4 mL) was added dropwise to a stirred solution of tert-
butyl ester 11 (0.93 mmol, 0.50 g) in dry CH2Cl2 (20 mL) under argon atmosphere, cooled 
to 0 C. The solution was stirred for 2 h at 0 C and the solvent was removed in vacuo. The 
crude product was purified by flash chromatography on silica gel (CHCl3/MeOH 15:1) to 
yield 12 as a yellow oil. 
Yield: 75% 
1
H-NMR (CDCl3) δ: 0.93 (d, J= 6.4, 3H); 1.02 (d, J= 6.4 Hz, 3H); 1.24 (s, 9H); 1.97-2.12 
(m, 1H); 2.89-3.01 (m, 2H); 3.21-3.35 (m, 1H); 3.51-3.66 (m, 1H); 3.98 (d, J= 9.6 Hz , 
1H); 7.40-7.57 (m, 5H); 7.63-7.68 (m, 2H); 7.87-7.93 (m, 2H). 
13
C-NMR (CDCl3) δ: 
19.36; 19.80; 27.83; 29.27; 42.60; 48.24; 66.49; 82.00; 127.23; 127.54; 127.99; 128.41; 
129.03; 139.01; 139.30; 145.44; 169.65.  
 
Synthesis of (R)-tert-butyl 2-(N-(2-benzamidoethyl)-[1,1'-biphenyl]-4-ylsulfonamido)-3-
methylbutanoate (13). 
A solution of 12 (0.499 mmol, 0.273 g) in dry DMF (7 mL) was treated with benzoyl 
chloride (0.599 mmol, 0.07 mL) and N,N-diisopropylethylamine (0.998 mmol, 0.2 mL) 
under nitrogen atmosphere. The reaction mixture was stirred at RT for 18 h, then was 
diluted with EtOAc, washed with H2O, dried over Na2SO4 and evaporated. The crude was 
purified by flash chromatography (n-hexane/EtOAc 8:1) using a Isolute Flash Si II 
cartridge to give 13 as a yellow oil (0.190 g). 
Yield: 71% 
1
H-NMR (CDCl3) δ: 0.96 (d, J= 6.4 Hz, 3H); 1.04 (d, J= 6.4 Hz, 3H); 1.26 (s, 9H); 2.06-
2.25 (m, 1H); 3.50-3.62 (m, 1H); 3.70-3.76 (m, 2H); 4.01-4.09 (m, 2H); 7.37-7.69 (m, 
10H); 7.84-7.93 (m, 3H); 8.09-8.13 (m, 1H). 
 
Synthesis of (R)-2-(N-(2-benzamidoethyl)-[1,1'-biphenyl]-4-ylsulfonamido)-3-
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methylbutanoic acid (14). 
Trifluoroacetic acid (57 mmol, 1.5 mL) was added dropwise to a stirred solution of tert-
butyl ester 13 (0.354 mmol, 0.190 g) in freshly distilled CH2Cl2 (6 mL), cooled to 0 C. 
The solution was stirred for 5 h at 0 C and the solvent was removed in vacuo. The crude 
product was purified by trituration with n-hexane/Et2O to give 14 as a white solid.  
M.p.: 63 °C 
Yield: 93% 
1
H-NMR (CDCl3) δ: 0.91 (d, J= 6.2 Hz, 6H); 2.01-2.16 (m, 1H); 3.34-3.53 (m, 1H); 3.58-
3.83 (m, 3H); 4.11 (d, J= 10.4 Hz, 1H); 5.67 (br s, 1H); 7.33-7.55 (m, 9H); 7.60-7.64 (m, 
2H); 7.78-7.88 (m, 4H). 
13
C-NMR (CDCl3) δ: 19.71; 20.09; 28.89; 40.67; 44.51; 66.19; 
127.19; 127.41; 127.67; 128.14; 128.70; 129.16; 131.73; 133.97; 137.64; 139.15; 146.06; 
168.03; 172.86. 
 
Synthesis of (R)-N-(8-([1,1'-biphenyl]-4-ylsulfonyl)-7-isopropyl-2,2,3,3-tetramethyl-6-
oxo-4-oxa-5,8-diaza-3-siladecan-10-yl)benzamide (15). 
To a solution of the carboxylic acid 14 (0.329 mmol, 0.158 g,), in anhydrous CH2Cl2 (13.2 
mL), was added O-(tert-butyldimethyl-sylil) hydroxylamine (0.658 mmol, 0.097 g). The 
reaction mixture was cooled in an ice bath and gradually EDC (0.658 mmol, 0.126 g) was 
added. The reaction mixture was left under stirring at RT overnight. The reaction mixture 
was diluted with CH2Cl2 (8 mL) and evaporated at RT, obtaining a yellow-brown oil. The 
crude was purified by chromatography, providing 0.079 g of compound 15, as brown oil. 
Chromatographic conditions: Eluent Exane 4: 1 EtOAc. Isolute column (Si II) 10 g. 
Yield: 39% 
 
Synthesis of (R)-N-(2-(N-(1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-[1,1'-biphenyl]-
4-ylsulfonamido)ethyl)benzamide (LR32). 
Silyl precursor 15 (0.354 mmol, 0.190 g) was dissolved in dry CH2Cl2 (6 mL) and TFA (57 
mmol, 1.5 mL) was added dropwise at 0 °C. After 5 h of stirring the solvent was 
evaporated and the crude product was purified by trituration with n-hexane/Et2O to afford 
LR32 as a white solid. 
M.p. 80-85 °C 
Yield: 88% 
1
H-NMR (DMSO-d6) δ: 0.87-0.94 (m, 6H); 2.16-2.22 (m, 1H); 3.22-3.29 (m, 1H); 3.64-
3.76 (m, 3H); 3.99-4.06 (m, 1H); 7.47-7.59 (m, 6H); 7.77-7.99 (m, 8H); 8.64 (s, 1H); 10.88 
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(s, 1H). 
13
C-NMR (acetone-d6) δ: 19.52; 20.05; 41.06; 44.67; 64.46; 127.97; 128.21; 
128.68; 129.01; 129.17; 129.77; 131.76; 135.60; 139.66; 139.95; 145.98; 167.14. 
 
6.2.5 Synthesis of (2R,12R)-3,11-bis([1,1'-biphenyl]-4-ylsulfonyl)-2,12-diisopropyl-7-oxo-
3,6,8,11-tetraazatridecane-1,13-dioic acid (Scheme 4, compound CA11) and (2R,2'R)-2,2'-
((azanediylbis(ethane-2,1-diyl))bis(([1,1'-biphenyl]-4-ylsulfonyl)azanediyl))bis(3-
methylbutanoic acid) (Scheme 5, compound CA15). 
  
Synthesis of (2R,12R)-di-tert-butyl 3,11-bis([1,1'-biphenyl]-4-ylsulfonyl)-2,12-
diisopropyl-7-oxo-3,6,8,11-tetraazatridecane-1,13-dioate (16) and (2R,2'R)-di-tert-butyl 
2,2'-((azanediylbis(ethane-2,1-diyl))bis(([1,1'-biphenyl]-4-ylsulfonyl)azanediyl))bis(3-
methylbutanoate) (17)
23
. 
 
Compound 12, as free base (0.745 mmol, 0.0.322 g), was dissolved in anhydrous CH2Cl2 
(6.4 mL) and 1,1'-carbonyldiimidazole (0.410 mmol, 0.066 g) was added to the solution. 
The reaction mixture was left under stirring at RT overnight. The crude was diluted with 
CH2Cl2 (15 mL) and the organic phase was washed with H2O (2x5 mL), with brine (1x4 
mL) and dried over Na2SO4. The crude was purified by flash chromatography, providing 
compounds 16 and 17. 
Chromatographic conditions: Eluent Exane 2: 1 EtOAc. Flash column: h = 17 cm; d = 2 
cm. 
Yield: 16 (31%); 17 (4%). 
1
H-NMR (CDCl3) δ: 16: 0.95 (d, J= 6.4 Hz, 6H); 1.02 (d, J= 6.4 Hz, 6H); 1.25 (s, 18H); 
2.04-2.17 (m, 2H); 3.30-3.50 (m, 6H); 3.75-3.85 (m, 2H); 3.97 (d, J= 10.4 Hz, 2H); 5.32 
(br s, 2H); 7.40-7.58 (m, 10H); 7.65-7.69 (m, 4H); 7.88-7.92 (m, 4H).
 13
C-NMR (CDCl3) 
δ: 19.54; 20.20; 28.05; 29.87; 41.52; 45.27; 66.94; 82.27; 127.39; 127.77; 128.28; 128.54; 
129.14; 138.66; 139.52; 145.80; 158.00; 169.94. 
1
H-NMR (CDCl3) δ: 17: 0.98 (d, J= 6.6 Hz, 12H); 1.30 (s, 18H); 2.00-2.20 (m, 2H); 3.43-
3.57 (m, 4H); 3.64-3.73 (m, 4H); 4.03 (d, J= 10.1 Hz, 2H); 7.41-7.57 (m, 10H); 7.65-7.70 
(m, 4H); 7.78 (br s, 1H); 7.85-7.89 (m, 4H).
 13
C-NMR (CDCl3) δ: 20.24; 20.96; 28.72; 
                                                 
23
 K.Kaur, M.Jaina, S.I.Khanc, M.R. Jacobc, B.L. Tekwani c,S.Singhb, P.Singhb, R.Jaina. Amino acid, 
dipeptide and pseudodipeptide conjugates of ring-substituted 8-aminoquinolines: Synthesis and evaluation of 
antiinfective, b-haematininhibition and cytotoxic activities. J.Med. Chem. 2012, 52, 230-241 [64]. 
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30.23; 42.29; 44.73; 65.58; 83.77; 128.03; 128.56; 128.67; 129.41; 129.85; 138.79; 139.83; 
146.95; 171.60. 
 
Synthesis of (2R,12R)-3,11-bis([1,1'-biphenyl]-4-ylsulfonyl)-2,12-diisopropyl-7-oxo-
3,6,8,11-tetraazatridecane-1,13-dioic acid (CA11). 
To a solution of the tert-butyl ester 16 (0.100 mmol, 0.089 g,), in anhydrous CH2Cl2 (2 
mL), at 0 °C in a H2O/ice bath, under Argon, trifluoroacetic acid (11.4 mmol, 0.8 mL,) was 
added dropwise. The reaction mixture was left under stirring at 0 °C for 5h. The crude was 
diluited with CH2Cl2 (5 mL) and the organic solvent was evaporated at r.p.. The crude was 
triturated with Hexane and Et2O, to give CA11 as a white solid. 
Yield: 62% 
1
H-NMR (CDCl3) δ: 0.75 (d, J= 5.5 Hz, 6H); 0.86 (d, J= 5.5 Hz, 6H); 1.85-2.10 (m, 2H); 
3.15-3.49 (m, 6H); 3.50-3.70 (m, 2H); 3.99 (d, J= 10.4 Hz, 2H); 6.29 (br s, 2H); 7.39-7.45 
(m, 6H); 7.52-7.55 (m, 4H); 7.61-7.65 (m, 4H); 7.83-7.87 (m, 4H).
 13
C-NMR (CDCl3) δ: 
19.67; 19.93; 29.89; 40.98; 44.85; 66.25; 127.39; 127.67; 128.12; 128.65; 129.14; 138.03; 
139.19; 145.86; 159.51; 174.10. 
 
Synthesis of (2R,2'R)-2,2'-((azanediylbis(ethane-2,1-diyl))bis(([1,1'-biphenyl]-4-
ylsulfonyl)azanediyl))bis(3-methylbutanoic acid) (CA15). 
To a solution of the tert-butyl ester 17 (0.0248 mmol, 0.021 g), in anhydrous CH2Cl2 (1 
mL), at 0 °C in a H2O/ice bath, under Argon, trifluoroacetic acid (2.82 mmol, 0.22 mL) 
was added dropwise. The reaction mixture was left under stirring at 0 °C for 5h. The crude 
was diluited with CH2Cl2 (5 mL) and the organic solvent was evaporated. The crude was 
triturated with Hexane and Et2O to give a white solid. 
Yield: 48% 
1
H-NMR (CDCl3) δ: 0.98 (d, J= 6.6 Hz, 12H); 2.00-2.20 (m, 2H); 3.43-3.57 (m, 4H); 
3.64-3.73 (m, 4H); 4.03 (d, J= 10.1 Hz, 2H); 7.41-7.57 (m, 10H); 7.65-7.70 (m, 4H); 7.85-
7.89 (m, 4H). 
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6.2.6 Synthesis of (R)-4-([1,1'-biphenyl]-4-ylsulfonyl)-N-(2-(N-((R)-1-(hydroxyamino)-3-
methyl-1-oxobutan-2-yl)-[1,1'-biphenyl]-4-ylsulfonamido)ethyl)-3-isopropyl-2-
oxopiperazine-1-carboxamide (Scheme 5, compound CA14_2). 
 
Synthesis of (R)-4-([1,1'-biphenyl]-4-ylsulfonyl)-N-((R)-8-([1,1'-biphenyl]-4-ylsulfonyl)-
7-isopropyl-2,2,3,3-tetramethyl-6-oxo-4-oxa-5,8-diaza-3-siladecan-10-yl)-3-isopropyl-2-
oxopiperazine-1-carboxamide (18). 
CA11 (0.113 mmol, 0.088 g) was dissolved in anhydrous CH2Cl2 (3 mL) and O-(tert-
butyldimethyl-silyl) hydroxylamine (0.226 mmol, 0.033 g) and EDC (0.339 mmol, 0.065 
g) were added to the solution. The reaction mixture was left under stirring at RT overnight. 
The crude was diluted with CH2Cl2 (5 mL) and the organic phase was washed with H2O 
(2x4 mL) and dried over Na2SO4. The crude was purified by chromatography, obtaining the 
cyclic intermediate 18 as a yellow oil.  
Chromatographic conditions: Eluent Exane 3: 1 EtOAc. Isolute column (Si II) 10 g. 
Yield: 20% 
1
H-NMR (CDCl3) δ: 0.16 (s, 3H); 0.18 (s, 3H); 0.83-0.87 (m, 6H); 0.96 (s, 9H); 1.05 (d, 
J= 6.8Hz, 3H); 1.16 (d, J= 6.8 Hz, 3H); 2.04-2.20 (m, 2H); 3.10-3.24 (m, 1H); 3.36-3.74 
(m, 7H); 4.11 (d, J= 8.8 Hz, 1H); 4.16-4.30 (m, 1H); 7.42-7.48 (m, 6H); 7.57-7.61 (m, 4H); 
7.69-7.73 (m, 4H); 7.81-7.86 (m, 4H); 8.53 (s, 1H); 8.88 (t, 1H). 
 
Synthesis of (R)-4-([1,1'-biphenyl]-4-ylsulfonyl)-N-(2-(N-((R)-1-(hydroxyamino)-3-
methyl-1-oxobutan-2-yl)-[1,1'-biphenyl]-4-ylsulfonamido)ethyl)-3-isopropyl-2-
oxopiperazine-1-carboxamide (CA14_2). 
The compound 18 (0.0193 mmol, 0.020 g), was dissolved in anhydrous CH2Cl2 (1 mL), at 
0 °C in a H2O/ice bath, under Argon and trifluoroacetic acid (2.20 mmol, 0.17 mL) was 
added dropwise to the solution. The reaction mixture was left under stirring at 0 °C for 5h. 
The crude was diluited with CH2Cl2 (5 mL) and the organic solvent was evaporated. The 
crude product was triturated with Hexane and Et2O, obtaining CA14_2 as a white solid. 
Yield: 60% 
1
H-NMR (CD3CN) δ: 
1
H-NMR (CD3CN) δ: 0.68 (d, J= 6.8 Hz, 3H); 0.80 (d, J= 6.8 Hz, 
3H); 0.99 (d, J= 6.8 Hz, 3H); 1.00 (d, J= 6.8 Hz, 3H); 2.01-2.19 (m, 2H); 3.14-3.36 (m, 
2H); 3.40-3.47 (m, 2H); 3.51-3.61 (m, 3H); 3.73-3.97 (m, 1H); 4.05 (d, J= 9.1 Hz, 1H); 
4.09-4.15 (m, 1H); 7.39-7.54 (m, 6H); 7.64-7.69 (m, 4H); 7.71-7.91 (m, 8H); 8.67 (t, J= 
4.6 Hz; 1H); 9.27 (s, 1H).
 13
C-NMR (CD3CN) δ: 19.31; 19.58; 19.79; 20.45; 28.64; 30.30; 
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31.92; 39.33; 41.30; 42.74; 44.23; 64.12; 67.15; 78.39; 79.10; 128.18; 128.44; 128.75; 
128.93; 129.57; 130.07; 137.39; 139.15; 139.72; 139.83; 146.12; 146.64; 154.30; 167.44; 
171.80. 
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